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Abstract

Serine Phosphorylation of the Small Phosphoprotein ICAP1 Inhibits Its
Nuclear Accumulation

Valerie Liao Su
2021

Cerebral cavernous malformations (CCMs) are neurovascular abnormalities
characterized by thin, leaky blood vessels resulting in lesions that predispose to
hemorrhages, stroke, epilepsy, and focal neurological deficits. Familial CCMs arise
due to loss-of-function mutations in genes encoding one of three CCM complex
proteins, KRIT1, CCM2, or CCM3. These widely-expressed, multi-functional
adaptor proteins can assemble into a CCM protein complex and either alone, or in
complex, modulate signaling pathways that influence cell adhesion, cell
contractility, cytoskeletal reorganization and gene expression. While recent
advances, including analysis of the structures and interactions of CCM proteins,
have allowed substantial progress towards understanding the molecular bases for
CCM protein function and how their disruption leads to disease, key unanswered
questions remain, including: 1) what biochemical signals regulate the localization
of the CCM proteins and their subsequent function?, and 2) how do the various
molecular pathways interplay and result in CCM pathogenesis when perturbed?
My dissertation studies aim to tackle these questions.
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In this body of work, I first review CCM protein signaling with a focus on three
pathways which have generated the most interest – the RhoA-ROCK, the MEKK3MEK5-ERK5-KLF2/4, and cell junctional signaling pathways – but also consider
ICAP1-β1 integrin and Cdc42 signaling. I discuss emerging links between these
pathways and the processes that drive disease pathology and highlight open areas
– among them, the role of subcellular localization in the control of CCM protein
activity.

In Chapter 2, I identify serine phosphorylation as a key factor in preventing nuclear
accumulation of ICAP1 and the ICAP1/KRIT1 complex. Very few biochemical
triggers that govern localization of proteins involved in CCM signaling have been
identified, and much remains unknown including how these triggers occur
mechanistically. My studies add to this field of knowledge by identifying a
mechanism that regulates localization of ICAP1 and the ICAP1:KRIT1 complex,
presumably impacting their as yet unidentified nuclear functions. I use quantitative
microscopy to demonstrate that phosphorylation-mimicking mutations at Ser10, or
to a lesser extent at Ser25, within ICAP1’s N-terminal region inhibits ICAP1 nuclear
accumulation. I further demonstrate that p21-activated kinase 4 (PAK4) can
phosphorylate ICAP1 at Ser10 in vitro and in cultured cells, and that active PAK4
inhibits ICAP1 nuclear accumulation in a Ser10-dependent manner. Finally, I show
that ICAP1 phosphorylation controls nuclear localization of the ICAP1/KRIT1
complex. This work is the first to identify a biochemical mechanism to regulate
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localization of ICAP1 and the ICAP1:KRIT1 complex, potentially influencing their
functions in CCM signaling and vascular development.

In the appendix, I investigate the KRIT1:CCM2 binding stoichiometry and
interaction, and how these impact relevant phenotypes including: MEKK3-MEK5ERK5-KLF2/4 signaling, cell growth, endothelial network formation, and
KRIT1:CCM2 protein stability. My preliminary studies indicate that KRIT1 or CCM2
knockdown in EA.hy926 human endothelial-like cells upregulates KFL2 and KLF4
mRNA levels, impairs cell growth, and perturbs network formation. Further work is
needed to test whether wildtype or binding defective KRIT1 or CCM2 rescue these
phenotypes. Ultimately, this work will reveal the signaling interplay between key
CCM proteins and partners and may reveal how abnormal signaling results in CCM
pathogenesis.
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Chapter 1: Introduction
1.1: Introduction to Cerebral Cavernous Malformations
1.1.1: What are CCMs?
Cerebral cavernous malformations or CCMs are vascular malformations found
predominantly in the central nervous system. They are characterized by thin, leaky
vessels that exhibit low pressure and low flow, contributing to dark red, blood filled
vascular lesions with a mulberry like appearance. Due to microhemorrhages and
thrombosis, hemosiderin deposits and gliotic tissue often surround the lesions
resulting in dysfunctional brain parenchyma as revealed by electron microscopy
(McCormick, 1966; Wong et al., 2000; Tanriover et al., 2013; Mouchtouris et al.,
2015). CCMs are collections of enlarged, densely packed vascular sinusoids with
an abnormal structure lined with a single layer of endothelial cells (Wong et al.,
2000). They lack vessel wall elements and are embedded in a collagen matrix
without intervening brain parenchyma (Wong et al., 2000). These cells further have
decreased numbers of neighboring pericytes, astrocytes, and vascular smooth
muscle cells, all of which contribute to the thin and leaky vascular walls that are
prone to rupture (Wong et al., 2000; Haasdijk et al., 2012; Tanriover et al., 2013;
Draheim et al., 2014).

1.1.2: CCM prevalence
CCMs are the second most common type of central nervous system vascular
lesions after developmental venous abnormalities (DVAs), and comprise 5-15% of
all neurovascular malformations (Berry et al., 1966; McCormick, 1966; McCormick
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et al., 1968; Giombini and Morello, 1978; Otten et al., 1989; Robinson et al., 1991;
Sage et al., 1993; Vernooij et al., 2007; Haasdijk et al., 2012; Bos et al., 2016;
Flemming et al., 2017). The prevalence in the general population is between 0.10.8% (Maraire and Awad, 1995; Moriarity et al., 1999; Haasdijk et al., 2012;
Mouchtouris et al., 2015). Young age (Barker et al., 2001; Dalyai et al., 2011),
female gender (Robinson et al., 1991; Porter et al., 1999), and the location, size
and multiplicity of lesions may lead to increased CCM development (Gross and
Du, 2017). However, the most significant determinant is prior CCM presentation
with hemorrhage and prior CCM location in the brainstem (Horne et al., 2016;
Gross and Du, 2017). A 2016 meta-analysis study using data from 1620 individual
CCM-diagnosed patients from 7 cohorts reports that the 5-year risk for developing
symptomatic intracranial hemorrhages (ICH) is 15.8% (Horne et al., 2016),
showing a significant risk of reoccurrence. Notably, the 5 year risk associated with
recurrent ICH increases to 29.5% after the first CCM bleed (Poorthuis et al., 2013).

1.1.3: Clinical symptoms of CCMs
About 60% of CCMs are clinically asymptomatic (Morris et al., 2009; Al-Holou et
al., 2012; Moore et al., 2014) and are most often discovered upon brain magnetic
resonance imaging (MRI) when patients seek other treatments (Vernooij et al.,
2007). The chance of hemorrhage in these cases is low as the lesions
predominantly exhibit slow oozing of blood and thrombosis within the lesion
confines. However, as the lesion continues to grow and/or blood escapes,
symptoms manifest due to nerve cell destruction, accumulation of hemosiderin
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deposits, and inflammation (Washington et al., 2010). Symptoms include seizures
(20-70%), focal neurological symptoms (e.g., double vision, nausea, and mobility
problems) (25-50%), hemorrhages (25-32%), or headaches (10-30%) (Morrison
and Akers, 1993; Denier et al., 2004b; Horne et al., 2016). Hemorrhages are the
most detrimental symptom and often require surgical resection for treatment
(Akers et al., 2017).

While CCMs can occur anywhere in the body (e.g., skin (Labauge et al., 1999; Oka
et al., 2017), retina (Boulday et al., 2011) and liver (Yang et al., 2017)), they are
almost exclusively found and only show serious signs in the brain or spinal cord.
Brain cavernous malformations typically present in the cerebrum (~65%),
brainstem (14.4%), and cerebellum (8.2%) (Amin-Hanjani et al., 1998). Based on
the brain location, the severity and presentation of symptoms differs (Amin-Hanjani
et al., 1998). For instance, infratentorial lesions (e.g., cerebellum) present a higher
risk of developing hemorrhage compared to supratentorial lesions (e.g., cerebrum)
(Mouchtouris et al., 2015). Additionally, seizures are the most common symptom
for cerebral CCMs (Englot et al., 2011), headaches and hemorrhages for
cerebellar CCMs (de Oliveira et al., 2006), and cranial neuropathies for brain stem
CCMs (Gross et al., 2013). Notably, while observational measures and surgical
resection are largely able to manage cerebellar and cerebral CCMs, brainstem
CCMs are highly risky to treat due to their deep-seated location (Abla et al., 2011).
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There are limited data on cavernous malformations in the spinal cord; however,
one meta-data analysis of 632 spinal cavernoma cases from 40 studies shows an
annual rate of hemorrhage of 2.1% with associated cerebral cavernomas found in
16.5% of patients (Badhiwala et al., 2014). Spinal cord cavernomas appear more
severe than cerebral malformations as 89.9% of these patients underwent surgical
resection

(Badhiwala

et

al.,

2014).

Symptoms associated

with

spinal

malformations include motor (60.5%), sensory (57.8%), pain (33.8%), and bladder
and/or bowel (23.6%) (Badhiwala et al., 2014). 38% of cases were cervical, 55.2%
thoracic, 2.4% cervicothoracic, and 2.1% lumbar (Badhiwala et al., 2014). Another
meta-analysis study compiling 27 publications with 352 patients also showed
similar rates of hemorrhage, symptoms, location of cavernomas, recurrence, and
surgical resection (Gross et al., 2010).

1.1.4: Genetics of CCMs
CCMs are either sporadic or familial with the latter making up about 20% of cases
(Petersen et al., 2010; Riant et al., 2010). Familial CCMs are more severe and
patients present with multiple lesions and increased hemorrhage rates, compared
to sporadic CCMs which typically present with a single lesion (Rigamonti et al.,
1988; Petersen et al., 2010). Familial CCMs result from mutations in one of the
three genes, KRIT1, CCM2, or CCM3, and are autosomal dominant, while sporadic
mutations most likely arise from a germline mutation or a somatic mutation in a
single cell (Plummer et al., 2005; Faurobert and Albiges-Rizo, 2010). In nearly all
familial cases and in about 57% of sporadic cases with multiple lesions, mutation
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in at least one CCM gene has been identified (Denier et al., 2006; Cavalcanti et
al., 2012; D’Angelo et al., 2013; Riant et al., 2013). Only a minority of sporadic
cases are due to germline mutations as studies have reported about 1.3-5.5%
germline mutations in CCM1, about 2.5% in CCM2, and 0% in CCM3 (Verlaan et
al., 2004; Denier et al., 2006; Felbor et al., 2007; D’Angelo et al., 2011, 2013;
Choquet et al., 2015). Additionally, in a few CCM cases, mosaicism resulting from
de novo germline as well as early and late postzygotic mutations have been
reported (Rath et al., 2016, 2020).

Lesion genesis is thought to arise from a two-hit mechanism, where loss of both
copies of one of the CCM genes must occur. In most cases, a germline, familial
mutation is accompanied by a second somatic, sporadic local hit to remove the
remaining wildtype copy leading to homozygous loss-of-function at the CCM locus
(Akers et al., 2009; McDonald et al., 2011). Mouse models have been generated
that support this hypothesis. Heterozygous Krit1 knockout mice do not normally
recapitulate disease phenotypes (McDonald et al., 2011). However, when these
mice are crossed into a p53 knockout background that mimics genomic instability
to increase the somatic mutation rate, they develop lesions resembling human
CCMs (Plummer et al., 2004; Shenkar et al., 2008). Further, Krit1+/- mice crossed
into a mismatch repair-deficient Msh2-/- background also display CCM lesions
(McDonald et al., 2011). Notably, at late stages, these lesions exhibit
characteristics consistent with human CCMs such as: hemosiderin deposits,
immune cell infiltration, increased ROCK activity, and increased endothelial cell
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proliferation (McDonald et al., 2011). Additionally, using a somatic mutation
detection strategy of multiple cycles of amplification, subcloning, and sequencing,
another study identified biallelic germline and somatic mutations in KRIT1, CCM2,
or CCM3 in human CCM lesion samples (Akers et al., 2009). This study further
reported by laser capture microscopy that the somatic mutations were found only
in endothelial cells and not in other cells of the neurovasculature, suggesting the
importance of the CCM proteins for vessel integrity.

1.1.5: CCM pathogenesis
Loss of CCM3 in neuroglia or mural cells produces dilated vasculature and
vascular lesions (Louvi et al., 2011; Wang Kang et al., 2020); however, neural or
smooth muscle-specific deletion of CCM2 did not recapitulate CCMs (Boulday et
al., 2009; Cunningham et al., 2011), suggesting that the CCM proteins may be
differentially expressed or their distinct signaling pathways may affect their function
in different cell types. Therefore, while other cell types may play a contributing role
(e.g., neuroglia, pericytes, smooth muscle cells, astrocytes), my dissertation
research focused on the clear impact of endothelial cells on CCM pathogenesis.
Indeed, endothelial specific deletion of Krit1, Ccm2, or Ccm3 in mouse models
results in lesions in the brain mimicking human CCMs (Whitehead et al., 2004;
Boulday et al., 2009, 2011; Maddaluno et al., 2013; Shenkar et al., 2015; Zhou et
al., 2016b, 2016a). As a result of KRIT1, CCM2, or CCM3 loss, cultured endothelial
cells and tissue from animal and human CCM lesions display perturbed β-catenin
(Glading and Ginsberg, 2010; Bravi et al., 2015), TGF-β/BMP (Maddaluno et al.,
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2013; Bravi et al., 2015; Cuttano et al., 2016), Notch (Wüstehube et al., 2010; You
et al., 2013; Schulz et al., 2015), β1 integrin (Tanjore et al., 2008; Faurobert et al.,
2013; Macek Jilkova et al., 2014; Renz et al., 2015), RhoA/ROCK (Whitehead et
al., 2009; Borikova et al., 2010; Stockton et al., 2010; Hartmann et al., 2015;
Lisowska et al., 2018), and MEKK3/MEK5/ERK5/KLF2/4 (Zhou et al., 2015a;
Cuttano et al., 2016; Zhou et al., 2016b; Choi et al., 2018) protein levels. These
molecular changes contribute to CCM pathogenesis through activating widescale
processes such as angiogenesis (Liu et al., 2010; Wüstehube et al., 2010; Zhu et
al., 2010; Renz et al., 2015; Retta and Glading, 2016), inflammation (Corr et al.,
2012; Retta and Glading, 2016), oxidative stress (Retta and Glading, 2016; Goitre
et al., 2017), and endothelial to mesenchymal transition (EndMT) (Maddaluno et
al., 2013; Cuttano et al., 2016; Retta and Glading, 2016; Zhou et al., 2016b), and
ultimately contribute to the abnormal architecture and leakiness of brain blood
vessels characteristic of CCMs. In summary, loss of KRIT1, CCM2, or CCM3
perturbs various signaling proteins and pathways that impact processes regulating
vascular stability, resulting in CCM pathogenesis.

1.2: The CCM Proteins
1.2.1: The CCM Protein Complex
Mutations in any one of three genes (KRIT1/CCM1, CCM2, or CCM3/PDCD10)
result in CCM disease. In 1994, Kurth et al. mapped CCM1 to chromosome 7p as
the first gene linked to CCM disease using linkage analysis (Kurth et al., 1994).
The precise location was mapped to a 4-cM segment of the human 7q21-q22,
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bounded by D7S2410 and D7S689 (Günel et al., 1995; Johnson et al., 1995). In
1999, KRIT1 was identified as the CCM1 gene using a positional cloning strategy
and transcriptional and physical mapping (Couteulx et al., 1999; Sahoo et al.,
1999). However, the identification of patients with CCM lesions who did not contain
CCM1 mutations led researchers to seek additional CCM disease-associated
genes. The CCM2 gene was linked to 7p15-p13, spanning a 11 cM segment
between D7S2846 and D7S1818 using multilocus and multipoint analysis (Craig
et al., 1998), and was confirmed to be located on 7p13 (Denier et al., 2004b). In
2003 and 2004, MGC4607 was identified as the CCM2 gene (Liquori et al., 2003;
Denier et al., 2004a). The third CCM3 locus, PDCD10/CCM3, is located on 3q25.227 within a 22-cM interval flanked by D3S1763 and D3S1262 (Craig et al., 1998;
Bergametti et al., 2005; Guclu et al., 2005).

The frequency of mutations in individuals with CCM ranges from between 53-65%
for KRIT1, 15-19% for CCM2, and 10-16% for CCM3 (Wang, 2005; Riant et al.,
2010). Loss of function mutations in these genes including nonsense, frameshift,
and splice site mutations resulting in a premature stop codon are the most
common; however, large deletions and insertions have also been observed (CavéRiant et al., 2002a; Akers et al., 2017). More than 100 distinct KRIT1, 30 CCM2,
and 20 CCM3 mutations have been identified (Draheim et al., 2014; Kim, 2016).
KRIT1, CCM2, and CCM3 encode the protein products: KRIT1, CCM2, and CCM3,
respectively. At the molecular level, KRIT1, CCM2, and CCM3 comprise the CCM
protein complex in which CCM2 binds to both KRIT1 and CCM3 (Fig. 1.1). The
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three CCM proteins stabilize each other, e.g., loss of KRIT1 leads to loss of CCM2
and vice versa (Stockton et al., 2010; Faurobert et al., 2013; Draheim et al., 2015).
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Fig. 1.1: Domain architecture of the CCM Protein Complex.
KRIT1 comprises a Nudix domain, three NPx(Y/F) motifs, an ankyrin repeat
domain, and a FERM (band 4.1, ezrin, radixin, moesin) domain. CCM2 comprises
a phosphotyrosine binding domain (PTB) domain, a LD-like motif, and a harmonin
homology domain (HHD). CCM3 is made up of a dimerization domain and focal
adhesion targeting-homology (FAT-H) domain. The 3rd or potentially the 2nd NPxF
motifs of KRIT1 bind to the PTB domain of CCM2, while the LD-like motif of CCM2
binds the FAT-H domain of CCM3.
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Interestingly, while KRIT1, CCM2, and CCM3 encode for three very different
proteins, a question that first initiated the field is how loss of each protein produces
similar disease phenotypes. This led researchers to question whether the proteins
are part of the same signaling pathway or on parallel pathways, triggering
researchers to delve into the molecular pathways associated with each KRIT1,
CCM2, CCM3 and how they contribute to CCM disease. For the remainder of
Chapter 1, I will review the signaling interplay of the three CCM proteins, their
downstream signaling partners which have generated the most interest including
the RhoA-ROCK, the MEKK3-MEK5-ERK5-KLF2/4, and cell junctional signaling
pathways, and finally the large-scale processes that contribute to CCM
pathogenesis when perturbed.

1.2.2: KRIT1
KRIT1 is a 736 amino acid protein. Over the past decade, crystallography has
established that it consists of a N-terminal Nudix domain, three Asn-Pro-X-Tyr/Phe
(NPx(Y/F)) motifs, a C-terminal ankyrin repeat domain (ARD) and FERM (band
4.1, ezrin, radixin, moesin) domain module (Francalanci et al., 2009; Li et al., 2012;
Gingras et al., 2013; Liu et al., 2013; Fisher et al., 2015b; Zhang et al., 2015) (Fig.
1.2). The domain architecture points to an adaptor protein role for KRIT1 as
NPxY/F motifs, ARDs and FERM domains are all recognized as interaction
modules. The discovery of an N-terminal Nudix domain was unexpected (Liu et al.,
2013), but the KRIT1 Nudix appears to lack the hydrolase activity normally
associated with Nudix domains and might more accurately be described as a
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pseudo-Nudix. While its function remains unknown, like other pseudo-enzymes
(Stiegler and Boggon, 2018; Ribeiro et al., 2019), it seems likely to mediate
interactions with other binding partners.

KRIT1 was first identified as a Rap1-binding protein in a yeast two-hybrid screen
(Serebriiskii et al., 1997). Binding occurs via the KRIT1 FERM domain (Li et al.,
2012) and, as discussed in later sections, this allows Rap1 to localize KRIT1 to
junctions where Rap1, KRIT1, and associated proteins exert junction stabilizing
activity both by activating junctional tension and inhibiting radial tension (Glading
et al., 2007; Liu et al., 2011). The KRIT1 FERM also binds the cytoplasmic tail of
the transmembrane protein HEG1 and this, in association with Rap1 binding,
contributes to junctional stability and signaling. KRIT1 may also associate with VEcadherin, α-catenin, β-catenin, AF-6, and p120-catenin at cell-cell junctions
influencing junctional stability and β-catenin-mediated transcription (Glading et al.,
2007; Glading and Ginsberg, 2010; Stockton et al., 2010) (Fig. 1.2). However, the
nature of these KRIT1 interactions, whether direct or indirect, remain to be
resolved.

The KRIT1 NPxY/F motifs support binding to the PTB domains of ICAP1 and
CCM2 (Liu et al., 2013; Fisher et al., 2015b). CCM2 binding involves the second
or third NPxY/F motifs but ICAP1 binding is restricted to the first NPxY/F motif.
This interaction stabilizes both KRIT1 and ICAP1 proteins, impairs the ability of
ICAP1 to inhibit integrin adhesion receptor activation (Faurobert et al., 2013; Liu
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et al., 2013; Draheim et al., 2016), and results in ICAP1-mediated nuclear import
of KRIT1 (Draheim et al., 2016; Su et al., 2020).

In addition to the well-characterized interactions of KRIT1 with ICAP1, CCM2,
HEG1 and Rap1, direct interactions with microtubules, possibly via a loop in the
KRIT1 Nudix domain, have been postulated (Gunel et al., 2002; Béraud-Dufour et
al., 2007) (Fig. 1.2). The ARD also contains evolutionarily-conserved surface
patches that suggest potential additional binding sites (Zhang et al., 2015), thus
there may be more to be learned about KRIT1 interactions. Furthermore, despite
the extensive advances revealing KRIT1 domain architecture, we still lack
structures of the intact protein and the potential for conformational regulation of
KRIT1 interactions remains (Liu et al., 2013; Fisher et al., 2015b; Zhang et al.,
2015).
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Figure 1.2: Domain architecture and interaction partners of KRIT1.
KRIT1 comprises a Nudix domain, three NPx(Y/F) motifs, an ankyrin repeat
domain (ARD), and a FERM (band 4.1, ezrin, radixin, moesin) domain. Tubulin
binds KRIT1’s Nudix domain, ICAP1 binds KRIT1’s 1st NPxY motif, SNX17 binds
KRIT1’s 2nd NPxY motif, CCM2 and CCM2L bind KRIT1’s 3rd or potentially 2nd
NPxF motif, and HEG1 and Rap1 bind KRIT1’s FERM domain. The binding site of
α-catenin, β-catenin, AF-6, VE-cadherin, and p120 to KRIT1 or whether the
interaction is direct or indirect is currently unclear.
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1.2.3: CCM2
CCM2 is a 444 amino acid protein made up of an N-terminal phosphotyrosine
binding domain (PTB) domain, a C-terminal harmonin homology domain (HHD),
and a middle LD-like motif linking the two domains (Draheim et al., 2015; Fisher et
al., 2015b) (Fig. 1.3). CCM2 directly interacts with KRIT1 through CCM2’s PTB
domain and KRIT1’s 2nd or 3rd NPx(Y/F) motifs (Fisher et al., 2015b) while the
CCM2 LD-like motif binds the FAT-H domain of CCM3 (Draheim et al., 2015).
CCM2 therefore bridges both KRIT1 and CCM3 supporting assembly of a CCM
protein complex. Interactions between the CCM proteins are important for protein
stability (Stockton et al., 2010; Faurobert et al., 2013; Draheim et al., 2015) and,
at least in the case of CCM2-CCM3, interactions are required for normal
endothelial network formation (Draheim et al., 2015). The HHD of CCM2 binds the
N-terminus of MEKK3, an upstream kinase in the p38 and ERK5 MAP kinase
(MAPK) pathways and this interaction appears necessary to prevent hyperactive
MEKK3-MEK5-ERK5 signaling which contributes to CCM pathogenesis (Fisher et
al., 2015a; Zhou et al., 2016b). However, CCM2 may also be required for activation
and regulation of the p38 pathway (Uhlik et al., 2003). Therefore, further study into
the mechanism by which CCM2 binding influences MEKK3 signaling is worth
exploring.

Like Krit1 knockout mice (Whitehead et al., 2004), Ccm2-/- mice die during
embryogenesis while Ccm2+/- mice exhibit the expected CCM lesion phenotype
(Boulday et al., 2009; Whitehead et al., 2009). In 2012, a paralog of CCM2, CCM2-
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like (CCM2L) was identified (Zheng et al., 2012). CCM2L has a similar domain
organization to CCM2 (Fig. 1.3) and, like CCM2, CCM2L uses its PTB domain to
bind KRIT1 and its HHD to bind and inhibit MEKK3 (Cullere et al. 2015), but notably
is unable to bind CCM3 (Zheng et al., 2012). Also like CCM2, CCM2L mediates
cardiovascular development as CCM2L deficiency in mice and zebrafish causes
perturbed circulation, a “big heart” phenotype with dilated atrial and inflow tracts
(Rosen et al., 2013; Cullere et al., 2015); however, it is unclear whether CCM2 and
CCM2L have redundant, opposing, or unrelated roles. For instance, CCM2 and
CCM2L compete for binding KRIT1 and MEKK3 (Zheng et al., 2012; Cullere et al.,
2015), and while loss of CCM2L in animal models may recapitulate phenotypes
resembling those of CCM2 loss, unlike Ccm2-/- mice, Ccm2L-/- null mice grow to
maturity in normal numbers and CCM2L appears to stabilize angiogenesis since
loss of CCM2L increases lumen formation in endothelial cells (Zheng et al., 2012).
Whether differences relate to competition between CCM2 and CCM2L for binding
to KRIT1 or to an inability of CCM2L to recruit CCM3 to the complex is yet to be
resolved, but CCM2 and CCM2L may have complementary roles in CCM signaling.
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Figure 1.3: Domain architecture and interaction partners of CCM2 and
CCM2L.
CCM2 comprises a N-terminal phosphotyrosine binding domain (PTB) domain, a
middle LD-like motif, and a C-terminal harmonin homology domain (HHD). Smurf1
and KRIT1 binds CCM2’s PTB domain, CCM3 binds CCM2’s LD-like motif, and
MEKK3 binds CCM2’s HHD. CCM2L comprises a PTB domain and HHD. KRIT1
binds CCM2L’s PTB domain and MEKK3 binds CCM2L’s HHD.
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1.2.4: CCM3
CCM3 (also called PDCD10) is a 212 amino acid protein made up of a N-terminal
dimerization domain and C-terminal focal adhesion targeting-homology (FAT-H)
domain (Li et al., 2010, 2011) (Fig. 1.4). CCM3 was the first of the CCM proteins
to be crystalized and this revealed that the dimerization domain allows
homodimerization (Li et al., 2011). The functional relevance of CCM3 homodimers
is not clear but the dimerization domain alternatively supports heterodimerization
with the germinal center kinase III (GCKIII) proteins (Ceccarelli et al., 2011),
suggesting important roles for CCM3 in GCKIII signaling. The FAT-H domain can
bind to many partners containing LD-like motifs, including CCM2, striatin, and
paxillin but also potentially to phosphatidylinositols (Hilder et al., 2007; Goudreault
et al., 2009; Dibble et al., 2010; Draheim et al., 2015; Padarti and Zhang, 2018)
(Fig. 1.4). The CCM2-CCM3 interaction stabilizes both proteins and is important
for endothelial network assembly (Draheim et al., 2015) but proteomic experiments
suggest that CCM3 mostly resides in the striatin-interacting phosphatase and
kinase (STRIPAK) multiprotein complex (Goudreault et al., 2009). There, together
with its interacting partners, it plays roles in vascular development, cell cycle
control, cell migration and vesicular trafficking (Kean et al., 2011; AbdelilahSeyfried et al., 2020). For example, CCM3 loss in cells impairs repositioning of
both the Golgi complex and centrosome towards the leading edge resulting in
inhibition of cell migration (Fidalgo et al., 2010; Kean et al., 2011), while increased
CCM3 expression increases cell migration (Fidalgo et al., 2010). Global or
endothelial deletion of Ccm3 in mice results in embryonic lethality due to vascular
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developmental defects and loss of VEGFR2 signaling (He et al., 2010b). Notably,
human CCM3 mutations have the most severe clinical consequences (Riant et al.,
2010; Shenkar et al., 2015) often with early onset of clinical features and an
increased CCM burden (Cigoli et al., 2014; Shenkar et al., 2015). These features
may suggest that loss of CCM3 leads to CCM pathogenesis through a different
mechanism than that of KRIT1 and CCM2. For instance, only CCM3 inhibits
exocytosis of angiopoitin-2 (ANG-2) from endothelial cells, and Ccm3 knockout
leads to increased ANG-2 secretion resulting in cavernoma development due to
decreased endothelial cell adhesion and pericyte coverage (Zhao et al., 2016;
Zhou et al., 2016a). Only CCM3 associates with VEGFR2, reducing its endocytosis
(He et al., 2010a), and CCM3 is required for normal endothelial cell proliferation
(Draheim et al., 2015). However, loss of CCM3, like loss of KRIT1 or CCM2,
impacts several core CCM signaling pathways arguing for a common mechanism
of pathogenesis that may be exacerbated in the absence of CCM3.
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Figure 1.4: Domain architecture and interaction partners of CCM3.
CCM3 comprises a N-terminal dimerization domain and C-terminal focal adhesion
targeting-homology (FAT-H) domain. Another CCM3 protein and GCKIII binds
CCM3 through its dimerization domain, while CCM2, striatin, and paxillin bind
CCM3 through its FAT-H domain. Binding of FAM65A and whether this is direct or
indirect is currently unclear.
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1.3: Protein Pathways Influencing CCM Signaling
Each of the CCM proteins forms distinct macromolecular complexes with other
proteins allowing them to impact numerous signaling pathways (Draheim et al.,
2014; Fisher and Boggon, 2014; Retta and Glading, 2016; Dejana et al., 2017;
Padarti and Zhang, 2018; Abdelilah-Seyfried et al., 2020; Wei et al., 2020).
Perturbation of several of these pathways has been strongly linked to CCM
disease, but the molecular bases of these connections have not always been fully
elucidated. Here, I focus on proteins relevant to CCM signaling, which can be
categorized as affecting the ICAP1/β1 integrin, RhoA-ROCK, junctional signaling,
and MEKK3-MEK5-ERK5-KLF2/4 pathways.

1.3.1: ICAP1
Integrin Cytoplasmic Domain-Associated Protein-1 (ICAP1) is a 200 amino acid
protein comprised of a N-terminal nuclear localization signal (NLS) and a
phosphotyrosine binding (PTB) domain that makes up nearly three-fourths of the
protein (Liu and Boggon, 2013). The PTB domain of ICAP1 was originally identified
to bind to the cytoplasmic domain of β1 integrins in yeast two-hybrid screens
(Chang et al., 1997; Zhang and Hemler, 1999). ICAP1 binding to β1 integrin tails
triggers inside-out signaling, in which the β1 integrin extracellular region becomes
bent with reduced affinity to the extracellular matrix, resulting in integrin inactivation
(Millon-Frémillon et al., 2008; Liu et al., 2013; Draheim et al., 2016). Since its
identification as a negative regulator of β1 integrins, ICAP1 has been reported to
influence integrin dependent processes such cell spreading (Degani et al., 2002;
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Millon-Frémillon et al., 2008), cell migration (Zhang and Hemler, 1999; Alvarez et
al., 2008; Millon-Frémillon et al., 2008), cell adhesion (Millon-Frémillon et al.,
2008), cell proliferation (Fournier et al., 2005a), and focal adhesion assembly
(Bouvard et al., 2003; Alvarez et al., 2008; Millon-Frémillon et al., 2008). In 2001,
a strong interaction was identified between the first NPxY motif of KRIT1 and the
PTB domain of ICAP1; therefore, binding of KRIT1 to ICAP1 results in β1 integrin
activation by disrupting the inhibitory ICAP1:β1 integrin interaction (Zhang et al.,
2001; Liu et al., 2013). The ICAP1:KRIT1 interaction stabilizes both proteins,
preventing their proteasomal degradation (Zawistowski, 2005; Faurobert et al.,
2013). Thus, while ICAP1 can negatively regulate integrins, its ability to bind and
stabilize KRIT1 may result in potentiating integrin dependent processes.

Although ICAP1 mutations have not been linked to CCM (Faurobert et al., 2013),
ICAP1 is important for normal vascular development (Brütsch et al., 2010;
Faurobert et al., 2013), likely in part due to its strong association with KRIT1.
ICAP1 overexpression in human umbilical vein endothelial cells inhibits endothelial
tube formation and sprouting while ICAP1 knockdown increases these processes
(Brütsch et al., 2010). Further, ICAP1-deficient endothelial cells grafted onto the
flanks of mice display increased sprouting angiogenesis and denser blood vessel
network formation (Brütsch et al., 2010). Compared to Icap1+/+ blood vessels,
Icap1-/- blood vessels are more dilated and their surrounding basal lamina structure
is disrupted and torn (Faurobert et al., 2013). Lastly, Icap1 null mice display striking
vascular abnormalities including massive dermal bleeding upon dissection and
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hemorrhagic kidneys, likely due to increased vessel permeability and dilation of
the blood vasculature (Faurobert et al., 2013).

1.3.2: β1 integrin
β1 integrin is the most commonly found subunit of integrin heterodimers (Howe
and Addison, 2012), cell surface adhesion receptors that bind extracellular matrix
ligands and mediate downstream intracellular signaling processes to regulate cell
proliferation, survival, and migration (Hynes, 1987). Supporting its role in CCM
signaling, β1 integrin plays a crucial role in vascular development and
angiogenesis (Avraamides et al., 2008; Carlson et al., 2008; Lei et al., 2008;
Tanjore et al., 2008; Yamamoto et al., 2015; Henning et al., 2019), and
downregulation of β1 integrin rescues vascular malformations in zebrafish (Renz
et al., 2015). At the molecular level, KRIT1 binds and stabilizes ICAP1, displacing
ICAP1 from binding to β1 integrin and increasing integrin activation (Liu et al.,
2013; Draheim et al., 2016). However, another study reports that loss of KRIT1
results in β1 integrin activation and signaling due to destabilized ICAP1 (Faurobert
et al., 2013). As such, the lesions of Krit1 and Ccm2-deficient mice exhibit altered
extracellular matrix remodeling due to increased β1 integrin activation (Faurobert
et al., 2013). These two conflicting views (Faurobert et al., 2013; Liu et al., 2013)
as to how KRIT1 loss impacts integrin activity are likely due to differences in ICAP1
and CCM protein expression levels as a result of differences in cell types used and
the extent of knockdown or overexpression. Further, CCM proteins may control
endothelial β1 integrin-dependent mechanotransduction in response to shear
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stress as silencing of CCM proteins restored the ability of EA.hy926 cells to
reorient to flow by releasing β1 integrin inhibition (Macek Jilkova et al., 2014).
Lastly, loss of CCM proteins results in upregulation of KLF2 and KLF4 (Renz et
al., 2015; Zhou et al., 2015a; Cuttano et al., 2016; Zhou et al., 2016b), and the
KLF2 upregulation requires β1 integrin (Renz et al., 2015). Therefore, various
reports showcase the impact of ICAP1 and CCM proteins on β1 integrin signaling;
however, the exact molecular pathway linking this association requires further
study.

1.3.3: RhoA/ROCK
KRIT1, CCM2, and CCM3 deficient endothelial cells and CCM human lesion
samples display activation of RhoA and its downstream effector ROCK1/2, which
consequently phosphorylates myosin light chain (MLC) and MLC phosphatase,
activating the former and inhibiting the latter (Whitehead et al., 2009; Stockton et
al., 2010; Zheng et al., 2010; Hartmann et al., 2015; Lisowska et al., 2018). This
increased RhoA/ROCK signaling results in actomyosin contractility and stress fiber
accumulation, yielding defects in cell migration, invasion, 3D tube formation and
maintenance of monolayer permeability barrier (Whitehead et al., 2009; Borikova
et al., 2010; Stockton et al., 2010; Faurobert et al., 2013; Lisowska et al., 2018).
Further, RhoA activation destabilizes endothelial adherens junctions, thereby
reducing endothelial barrier function and increasing vascular permeability (Cerutti
and Ridley, 2017). Notably, ROCK pharmacologic inhibition reversed the increase
in phospho MLC, actin stress fiber formation, and monolayer permeability seen in
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KRIT1, CCM2, or CCM3 RNAi knockdown endothelial cells (Whitehead et al.,
2009; Borikova et al., 2010; Stockton et al., 2010; Lisowska et al., 2018), and also
reversed the impaired pulmonary and cerebral vascular leakage seen in Krit1+/and Ccm2+/- heterozygous mice (Whitehead et al., 2009; Stockton et al., 2010).
Similarly, the ROCK inhibitors, fasudil and atorvastatin, have recently been shown
to reduce lesion burden in Ccm3 deficient mice (Shenkar Robert et al., 2019).
Altogether, these studies show that the KRIT1, CCM2, and CCM3 pathways all
involve RhoA/ROCK signaling, and inhibiting RhoA/ROCK activation may be a
viable pharmacologic CCM disease treatment option.

There are two isoforms of ROCK. While KRIT1 binds both ROCK1 and ROCK2,
KRIT1 impacts their functions differently, and ROCK1 and ROCK2 also function
differently in CCM signaling (Lisowska et al., 2018). For example, KRIT1 recruits
ROCK2 to VE-cadherin junctions while KRIT1 inhibits ROCK1 kinase activity to
ensure proper adhesion to the extracellular matrix and stabilize cell–cell junctions
(Lisowska et al., 2018). Notably, while ROCK2 knockdown phenocopies the heart
defects of kri-1 null zebrafish and the abnormal F-actin and focal adhesion
morphologies of KRIT1 and CCM2 null endothelial cells, ROCK1 knockdown
restores cortical actin organization and rescues cardiac cushions and ventricular
chamber formation in kri-1 mutant zebrafish (Lisowska et al., 2018). This suggests
that ROCK1, but not ROCK2, should be targeted for potential CCM therapeutics.
However, contrarily, a ROCK2 selective inhibitor is able to reduce brain lesions in
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mice (McKerracher et al., 2020), lending complexity to the signaling interplay
between the CCM proteins and ROCK1 versus ROCK2.

The exact molecular mechanisms by which loss of KRIT1, CCM2, or CCM3 results
in activation of the RhoA/ROCK pathway is uncertain. The PTB domain of CCM2
binds the Homologous to the E6-AP C Terminus (HECT) domain of the E3 ubiquitin
ligase Smurf1, leading to Smurf1’s colocalization with CCM2 at the cell periphery
(Crose et al., 2009). Smurf1 degrades RhoA (Crose et al., 2009); therefore, the
CCM2:Smurf1 interaction ostensibly prevents the hyperactivation of the ROCK
pathway seen in CCM lesions. Meanwhile, loss of CCM3 could alter RhoA/ROCK
activity through its interaction with FAM65A, an adapter and Rho effector protein
that binds active RhoA (Mardakheh et al., 2016). FAM65A also binds MST3 and
MST4 (Mardakheh et al., 2016), two additional members of the STRIPAK complex,
and loss of CCM3, MST3, and MST4 all result in activated RhoA/ROCK signaling
(Zheng et al., 2010). However, it is still unexplored whether the CCM3:FAM65A
interaction influences RhoA or ROCK activity (Mardakheh et al., 2016). How KRIT1
loss mechanistically results in RhoA/ROCK hyperactivation is also unclear;
though, one hypothesis is that KRIT1 loss leads to CCM2 loss (Zawistowski, 2005;
Faurobert et al., 2013) resulting in Smurf1’s inability to degrade RhoA (Crose et
al., 2009). Alternatively, KRIT1 loss leads to ICAP1 loss (Faurobert et al., 2013;
Liu et al., 2013), and could consequently affect ROCK activity since ICAP1 directly
binds ROCK1 and localizes it to membrane ruffles (Stroeken et al., 2006).
However, how ICAP1 impacts ROCK1 activity was not addressed in the study.
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Finally, another hypothesis is KRIT1 loss prevents Rap1 stabilization of Rasip1
and Rasip1’s binding partner the RhoA GAP ARHGAP29 at endothelial cell
junctions, resulting in increased stress fiber formation and cell contractility (see
Rap1 section for more details) (Glading et al., 2007; Xu et al., 2011; Post et al.,
2015).

1.3.4: Cdc42
Cdc42 is a small GTPase belonging to the Rho subfamily that was first discovered
to be essential for actin cytoskeletal dynamics and cell polarity (Johnson and
Pringle, 1990). Cdc42 plays a crucial role in the vasculature, and its deletion
inhibits angiogenesis while inducing aberrant vascular remodeling, defective Factin organization, and disorganized cell-cell junctions (Barry et al., 2015; Castro
et al., 2019). Loss of Cdc42 also impairs brain endothelial cell sprouting, branching
morphogenesis, axial polarity, and normal dispersion within brain tissue (Castro et
al., 2019). A recent report explored the role of Cdc42 in CCM signaling, and
showed that loss of KRIT1 and CCM2 inhibited Cdc42, leading to disorganized
endothelial junctions and increased vascular permeability (Castro et al., 2019).
Further, Cdc42 interacts with the CCM proteins, and CCM3 promotes Cdc42
activity in endothelial cells (Castro et al., 2019). In C. elegans, CCM3 enhances
Cdc42 signaling as ccm-3-/- null worms have severely reduced Cdc42 and active
Cdc42 protein levels in excretory canals (Lant et al., 2015). Further, cdc-42
ablation by mutation or RNAi caused canal truncations and canal cyst formation
similar to those seen in ccm-3 null c. elegans (Lant et al., 2015). Notably, in mice,
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post-natal endothelial specific deletion of Cdc42 elicits malformations reminiscent
of CCMs likely through increased MEKK3-MEK5-ERK5 signaling and consequent
increased KLF2/4 (Castro et al., 2019). Supporting this mechanism, genetic
inactivation of Klf4 attenuates the severity of vascular defects in Cdc42 mutant
mice.

1.3.5: Rap1 and other cell junction proteins
Rap1 (Rap1a and Rap1b) are Ras-like small G-proteins that cycle between a GTPbound active state and a GDP-bound inactive state. Rap1a and Rap1b double
knockout mice are embryonic lethal and display hemorrhages at mid-gestation
(Chrzanowska-Wodnicka et al., 2005; Li et al., 2007; Lakshmikanthan et al., 2015).
Rap1 localizes to cell-cell junctions to prevent leaky vasculature (Knox and Brown,
2002; Glading et al., 2007; Glading and Ginsberg, 2010), where it requires local
activation by Rap-GEFs, PDZ-GEF, and Epac (Pannekoek et al., 2011, 2013). At
the junctions, Rap1 ultimately induces circumferential actin bundle formation while
inhibiting radial stress fiber formation to regulate and potentiate cell junction
barriers (Ando et al., 2013). Importantly, Rap1 binds KRIT1 and regulates KRIT1’s
junctional localization and association with other junctional partners (Glading et al.,
2007) (Fig. 1.5). RNAi depletion of KRIT1 blocks Rap1’s ability to stabilize
endothelial cell junctions (Glading et al., 2007), showing the crucial interaction of
KRIT1 and Rap1 in preventing vascular leakage.
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KRIT1 has also been shown to co-immunoprecipitate with cell-junctional proteins
such as β-catenin, p120-catenin, α-catenin, AF-6, and vascular endothelium VEcadherin, indicating their associations in cells (Glading et al., 2007) (Fig. 1.5).
Notably, VE-cadherin is a critical vascular protein involved in CCM signaling. VEcadherin molecules function in the vasculature through homophilic interactions
across adherens junctions (Lampugnani et al., 2018). They also form complexes
with various cytoplasmic partners to mediate signaling. Of relevance, VE-cadherin
binds KRIT1 through β-catenin and localizes Rap1 to junctions (Glading et al.,
2007; Glading and Ginsberg, 2010). VE-cadherin further controls localization of
Rap1 GEFs at junctions (e.g., Epac and PDZ-GEF), where they activate Rap1 to
stabilize endothelial cell barriers (Glading et al., 2007; Lampugnani et al., 2010;
Pannekoek et al., 2011).

Other relevant vascular proteins associated with KRIT1 and Rap1 include: Rasip1,
which binds Rap1 and HEG1 (de Kreuk et al., 2016), and HEG1 which binds
Rasip1 and KRIT1 only if they are bound to active GTP-Rap1 (Gingras et al., 2012,
2013; de Kreuk et al., 2016) (Fig. 1.5). Therefore, binding of HEG1 to Rasip1
directs Rasip1’s recruitment to and stabilization at junctions in a Rap1-dependent
manner (de Kreuk et al., 2016). This HEG1:Rasip1 binding interaction is necessary
to inhibit ROCK activity and maintain endothelial cell junctional stability (de Kreuk
et al., 2016). Further, KRIT1’s C-terminal FERM domain binds HEG1 and this
interaction is crucial for KRIT1’s localization to the membrane, thereby supporting
cardiovascular development (Gingras et al., 2012). Consistent with HEG1 and
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Rasip1’s role in CCM signaling and vascular integrity, HEG1 is highly expressed
in the endothelium and Heg1-/- global knockout mice and zebrafish display
defective heart, blood vessel, and lymphatic vessel integrity (Mably et al., 2003;
Kleaveland et al., 2009), while mice lacking Rasip1 have impaired blood vessel
tubulogenesis and lumen formation (Xu et al., 2011).

Figure 1.5: Junctional signaling.
KRIT1 forms a complex with Rap1, HEG1, and Rasip1 that is important for their
recruitment to and stabilization of endothelial junctions. Rasip1 also binds Radil1
and ARHGAP29 and leads to their recruitment to junctions. This leads to inhibition
of Rho activity by ARHGAP29, inhibiting ROCK activation and downstream MLC
phosphorylation.
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1.3.6: MEKK3
Mitogen-activated protein kinase kinase kinase 3 (MEKK3) is a 622 amino acid
protein consisting of a N-terminal helix, a Phox/Bem1p (PB1) domain, and a Cterminal kinase domain (Fisher et al., 2015a), and is part of the p38 and ERK5
MAPK stress-activated protein kinase cascades. Hyperactivation of MEKK3, which
activates MEK5, then ERK5, and ultimately upregulates KLF2/4 transcription
factors (Zhou et al., 2015a, 2016b) (Fig. 1.6). As such, using an Nfatc1Cre allele to
delete MEKK3 in the endocardium, Nfatc1Cre; Map3K3fl/- mice show embryonic
lethality prior to E12.5, and E10.5 hearts reveal severe reductions in Klf2/4 (Zhou
et al., 2015a). Importantly, MEKK3 directly binds CCM2 in endothelial cells, and
evidence of MEKK3’s role in CCM pathogenesis comes from a disease-causing
human CCM2 mutation that abrogates the MEKK3 interaction without affecting
CCM complex formation (Zhou et al., 2015a). Notably, MEKK3 haplo-insufficiency
rescues the loss of cardiac jelly and changes in gene expression conferred by
endocardial KRIT1 deletion (Zhou et al., 2015a), and also rescues cardiac defects
in CCM-deficient embryonic mouse and fish hearts (Zhou et al., 2016b). Further,
Ponatinib, a compound capable of directly inhibiting MEKK3 kinase activity, can
prevent formation of new CCM lesions, reduce the growth of already formed
lesions, and normalize expression of KLF2/4 in neonatal mouse models of CCM
(Choi et al., 2018). Similarly, treatment of BIX02189, a highly specific MEK5
inhibitor, reduced levels of KLF2/4 and downstream factor ADAMTS5 in cultured
wild-type E10.5 explanted mice hearts (Zhou et al., 2015a). These studies reveal
a high importance of the CCM2:MEKK3 interaction in preventing downstream
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upregulation of KLF2/4 to deter CCM pathogenesis; however, how this
mechanistically occurs requires further study.
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Figure 1.6: The MEKK3-MEK5-ERK5-KLF2/4 signaling pathway.
Loss of KRIT1 or CCM2, activation of Cdc42 or TLR4, or other stimuli can result in
hyperactivation of the MEKK3-MEK5-ERK4 kinase cascade, leading to
upregulation of KLF2 and KLF4 transcription factors and changes in expression of
their transcriptional targets such as ADAMTS4, thrombomodulin (TM),
thrombospondin 1 (TSP1), bone morphogenic protein 6 (BMP6), and potentially
SLC39.
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1.3.7: KLF2 and KLF4
KLF2 and KLF4 are transcription factors that regulate crucial endothelial
responses to pressure and inflammation. For instance, HUVECs exposed to
laminar shear for 16 hours exhibit increased KLF2/4 and downstream ADAMTS4
expression, leading to degradation of versican (Zhou et al., 2015a). Further, global
deletion of either Klf2 or Klf4 in mice results in embryonic lethality or death shortly
after birth due to vascular defects like gross hemorrhaging (Kuo et al., 1997;
Chiplunkar et al., 2013; Sangwung et al., 2017). Inducible endothelial specific
knockout of Klf2 and Klf4 also results in vascular barrier disruption, systemic
coagulopathy, and ultimately rapid death of adult mice (Sangwung et al., 2017),
further showing crucial roles for KLF2/KLF4 in the vasculature. Several studies
have linked KLF2/KLF4 overexpression to loss of KRIT1, CCM2, or CCM3 that is
characteristic of CCM lesions (Zhou et al., 2015a; Cuttano et al., 2016; Zhou et al.,
2016b) (Fig. 1.6). Similarly, endothelial specific deletion of KRIT1, CCM2, and
CCM3 leads to KLF2/4 nuclear translocation and upregulation (Cuttano et al.,
2016; Zhou et al., 2016b). In neonatal mouse models of CCM disease, endothelial
loss of MEKK3, KLF2, or KLF4 prevents lesion formation and rescues lethality
(Cuttano et al., 2016; Zhou et al., 2016b). Furthermore, genetic inactivation of
KLF4 blocks the formation of CCM lesions and abrogates the mortality of mice with
endothelial specific ablation of KRIT1 by 75% (Cuttano et al., 2016). Therefore,
KLF2 and KLF4 are upregulated in CCM lesions and in KRIT1-, CCM2-, or CCM3deficient endothelial cells, and their downregulation can reverse CCM disease
phenotypes.
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Upregulated KLF2 and KLF4 further influence the expression of various proteins
relevant to vascular biology. For instance, the extracellular protease ADAMTS4,
which is important in cardiac development (Zhou et al., 2015a), and the growth
factor bone morphogenic protein 6, which may contribute to endothelial-tomesenchymal transition (EndMT), are upregulated downstream of MEKK3-MEK5ERK5-KLF2/4 signaling in CCM disease (Cuttano et al., 2016) (Fig. 1.6). More
recently, studies in C. elegans and zebrafish revealed KRIT1 and CCM2 regulation
of KLF-induced expression of a zinc transporter SLC39, with important non-cell
autonomous effects on apoptosis (Chapman et al., 2019), and studies in mice
showed KLF2/4-driven induction of microRNA-27a (miR-27a), a negative regulator
of VE-cadherin expression (Li et al., 2020). Preventing miR-27a interaction with
VE-cadherin mRNA restored endothelial barrier function in vitro and normalized
vasculature and reduced lesion formation and growth in CCM mouse models (Li
et al., 2020). While some key outputs from the KLF2/4 pathway relevant for CCM
have been resolved, additional targets of interest are still being identified.

1.3.8: Thrombomodulin
Thrombomodulin (TM, gene name THBD, an anti-blood clotting membrane protein
expressed in endothelial cells, was recently identified as being a downstream
target of KLF2/KLF4 and is involved in CCM signaling (Lopez-Ramirez et al., 2019)
(Fig. 1.6). TM levels are increased in human CCM lesions and in the plasma of
CCM patients (Lopez-Ramirez et al., 2019). Endothelial specific deletion of KRIT1

35

or CCM3 results in increased levels of vascular TM and Endothelial Protein C
Receptor (EPCR) due to upregulation of KLF2/KLF4 (Lopez-Ramirez et al., 2019).
Importantly, blocking antibodies against thrombomodulin and EPCR significantly
reduce CCM hemorrhage in CCM3 endothelial specific knockout mice (LopezRamirez et al., 2019). Consistent with this, genetic inactivation of 1 or 2 copies of
the Thbd gene decreases brain hemorrhage in these mice (Lopez-Ramirez et al.,
2019). Therefore, TM is upregulated in CCM patient lesions and inactivating TM
may reduce lesion burden.

1.3.9: Thrombospondin 1
Another protein linked to CCM disease through the KLF2/KLF4 pathway is
Thrombospondin 1 or TSP1 (gene name THBS1) (Lopez-Ramirez et al., 2017), a
potent endogenous angiogenesis inhibitor (Good et al., 1990). Acute KRIT1 gene
inactivation in brain microvascular endothelial cells (BMECs) leads to repression
of TSP1 due to upregulated KLF2/KLF4 (Lopez-Ramirez et al., 2017) (Fig. 1.6).
This results in heightened VEGF signaling and weakened tight junctions. Notably,
these phenotypes are reversed by in vitro reconstitution with full length TSP1 or
with 3TSR (the anti-angiogenic TSP1 fragment) (Lopez-Ramirez et al., 2017).
Further linking suppression of TSP1 to CCM pathogenesis is that inactivation of
one or two copies of Thbs1 further aggravated CCM lesion genesis and
pathogenesis (Lopez-Ramirez et al., 2017). Importantly, 3TSR administration
prevents the development of lesions in Krit1 endothelial-specific knockout mice
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(Lopez-Ramirez et al., 2017), indicating that normalization of TSP1 levels may
improve CCM patient outcomes.

1.3.10: Crosstalk between CCM signaling pathways
While the protein pathways influencing CCM signaling have been identified, how
they interact is still a nascent area of research. Interestingly, Rap1 and its
junctional partners appear to crosstalk with the Rho GTPases. In addition to
binding Rap1 and HEG1, Rasip1 also binds Radil and the RhoA RhoGAP
ARHGAP29 (Post et al., 2015) (Fig. 1.5). Activation of Rap1 not only localizes
Rasip1 and HEG1 to the plasma membrane, but also recruits Radil and
ARHGAP29 there as well (Glading et al., 2007; Post et al., 2015). Junctional
localization of Rap1 and its partners not only stabilizes endothelial barriers but
interestingly also appears to downregulate RhoA/ROCK signaling (Xu et al., 2011;
Post et al., 2013, 2015; de Kreuk et al., 2016). For instance, silencing of HEG1 in
HUVECs results in increased MLC phosphorylation and formation of actin stress
fibers that can be rescued by wildtype HEG1 but not a Rasip1-binding deficient
HEG1 mutant (de Kreuk et al., 2016). Furthermore, this Rasip1-binding deficient
HEG1 mutant failed to localize to junctions, and failed to rescue the increased
vascular permeability upon Rasip1 silencing, suggesting that the junctional
localization of Rasip1 is important for regulation of RhoA/ROCK and vascular
permeability (de Kreuk et al., 2016). Further supporting this model, knockdown of
Rasip1, ARHGAP29, or Radil leads to increased stress fiber assembly,
upregulated phospho-MLC and phospho-MYPT (a downstream target of
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ROCK1/2), increased levels of active RhoA, reduced cell spreading, defects in
lumen formation, and increased number of irregular junctions (Xu et al., 2011; Post
et al., 2013). Notably, these phenotypes can be rescued by RhoA knockdown or
treatment with ROCK inhibitors (Xu et al., 2011; Post et al., 2013). Further
evidence suggesting a crosstalk between the RhoA/ROCK and Rap1 pathways
come from the observation that RhoA knockdown results in increased endothelial
barrier function and tubulogenesis (Post et al., 2013; Barry et al., 2016), while
RhoA overexpression suppresses lumen formation (Bayless and Davis, 2002,
2004). Taken together, this suggests a potential model where activation of Rap1
results in localization of associated partners like Rasip1, Radil1, ARHGAP29 to
cell junctions where they function in stabilizing endothelial barriers, inducing cell
spreading, and reducing stress fiber formation by reducing RhoA activity (Fig. 1.5).

Interestingly, dysregulated β1 integrin may link the Rap1/junctional proteins and
RhoA/ROCK pathways. Indeed, Rap1 is known to activate integrins in multiple cell
types, including endothelial cells (Bos et al., 2003; Zhao et al., 2007; Boettner and
Van Aelst, 2009; Carmona et al., 2009). β1 integrin also has been reported to
localize VE-cadherin to cell-cell junctions, providing a mechanism for its role in cellcell junction integrity (Yamamoto et al., 2015). Consistent with this, loss of Rasip1
or ARHGAP29 in endothelial cells reduced activated β1 integrin by 70% and 80%,
respectively, and also suppressed β1 integrin adhesion to the ECM (Xu et al.,
2011). However, a different study reports that loss of KRIT1 or CCM2 results in
upregulated RhoA/ROCK signaling as a result of β1 integrin hyperactivation since
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silencing β1 integrin abolished the increase in RhoA-GTP (Faurobert et al., 2013).
Further supporting this model, the authors show ICAP1, KRIT1, or CCM2-depleted
HUVECs were elongated and displayed transverse bundles of actin stress fibers
(both signs of Rho activation), and that depleting β1 integrin blocked the formation
of these fibers (Faurobert et al., 2013). These two studies are seemingly
contradictory: Xu et al. report that loss of cell junctional proteins increases stress
fiber formation as a result of downregulated β1 integrin and hyperactivated RhoA
signaling, while Faurobert et al. report that loss of CCM proteins, which can
mislocalize Rap1 and junctional proteins (Glading et al., 2007; Glading and
Ginsberg, 2010), increases stress fiber formation as a result of hyperactivated β1
integrin and RhoA/ROCK signaling. Further studies are needed to resolve this
discrepancy. For instance, β1 integrin signaling impacts a wide range of
cytoskeletal and adhesion proteins, making it difficult to directly attribute the
increased RhoA/ROCK levels seen in KRIT1 and CCM2 depleted cells to changes
in β1 integrin signaling. Regardless, junctional proteins (e.g., KRIT1, Rap1,
Rasip1, HEG1) play crucial functions in stabilizing endothelial barriers and in
preventing RhoA/ROCK mediated cell contractility and stress fiber formation.

As introduced previously, loss of KRIT1, CCM2, or CCM3 which disrupts the
CCM2:MEKK3 interaction, results in activation of the MEKK3/MEK5/ERK5 kinase
cascade and consequent hyperactivation of the transcription factors KLF2 and
KLF4 (Cullere et al., 2015; Fisher et al., 2015a; Zhou et al., 2015a, 2016b) (Fig.
1.6). Since its initial discovery, additional partners have been identified to be
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relevant to this pathway. For instance, increased toll-like receptor 4 (TLR4)
expression due to inflammatory triggers or loss of Cdc42 results in activation of
MEKK3 and its downstream partners (Tang et al., 2017; Castro et al., 2019).

It is likely that the MEKK3/KLF2/4 pathway intersects with the Rap1/junctional
protein and RhoA/ROCK pathways. First, the important junctional protein VEcadherin is also inhibited by miR-27a, whose expression is induced by KLF2/4
downstream of CCM protein loss (Li et al., 2020). Second, Zhou et at. attempt to
connect the MEKK3/KLF2/4 and RhoA/ROCK pathways using neonatal mouse
models. Inducible endothelial specific heterozygous loss of Mekk3, Klf2, and Klf4
in a Krit1 mutant background results in significant prevention of CCM lesions and
normalization of phosphoMLC staining. (Zhou et al., 2016b). Further, agents that
can inhibit RhoA including hydroxyfasudil, Tempol and vitamin D3 failed to reverse
the increase in KLF2/4 mRNA levels seen in KRIT1 deficient endothelial cells
(Zhou et al., 2016b). Both findings suggest that changes in RhoA/ROCK activity
are downstream of changes in MEKK3 activity (Zhou et al., 2016b). Third, one
CCM

signaling

protein

that

impacts

the

MEKK3-MEK5-ERK5-KLF2/4,

Rap1/junctional protein, and RhoA/ROCK pathways is Cdc42. In addition to being
an upstream activator of MEKK3 (Castro et al., 2019), Cdc42 appears to function
downstream of Rap1 and junctional protein signaling. Consistent with this, Cdc42
activation is required for lumen formation in 3D collagen matrix assays (Bayless
and Davis, 2002; Iruela-Arispe and Davis, 2009; Sacharidou et al., 2010; Xu et al.,
2011). Mechanistically, depletion of Rasip1 or ARHGAP29 in HUVECs results in
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decreased levels of activated Cdc42 and downstream kinases (e.g., Pak4, Src, BRaf, C-Raf and Erk), suggesting that Cdc42 signals downstream of Rap1 and its
related junctional proteins (Xu et al., 2011). While the Rap1/junctional protein
pathway impacts both Cdc42 and RhoA activity, it appears that these two proteins
either lie on separate, parallel pathways or Cdc42 acts downstream of
RhoA/ROCK since Cdc42-depleted endothelial cells did not significantly change
RhoA activation levels (Castro et al., 2019) (Fig. 1.5). Collectively, these junctional
proteins appear to decrease RhoA signaling, while activating β1 integrin and
Cdc42 signaling to protect against CCM pathogenesis (Xu et al., 2011).

In conclusion, many complex protein pathways contribute to CCM pathogenesis,
but connections between pathways are only gradually being resolved. While in
some cases the exact molecular players linking loss of KRIT1, CCM2, or CCM3 to
lesion genesis remain unclear, emerging evidence suggests KLF2/4 expression
downstream of Cdc42, MEKK3 and integrin signaling lies upstream of alterations
in junctional proteins and ultimately of Rho activation.

1.4: Processes Contributing to CCM Pathogenesis
As described in the preceding section, dysregulation of various proteins within
different signaling pathways play a contributing role towards CCM pathogenesis.
As a result, some large-scale processes including oxidative stress, angiogenesis,
inflammation, Notch signaling, and the gut microbiome and barrier are also
perturbed and influence lesion genesis.
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1.4.1: Oxidative stress
Oxidative stress may be a microenvironmental second hit trigger to cause a
homozygous null KRIT1, CCM2, or CCM3 allele (Retta and Glading, 2016). As
such, oxidative stress is implicated in all the major changes related to CCM
disease including increased β1 integrin activation, vascular permeability, and
angiogenic activity (Retta and Glading, 2016). KRIT1 is believed to play a
protective role by suppressing pro-oxidant and pro-inflammatory pathways, e.g.,
through JNK/c-Jun-dependent stress response signaling and modulating the levels
of antioxidant proteins FoxO1, SOD2, and Sirt1 (Goitre et al., 2010, 2014). KRIT1deficient cells show elevated reactive oxygen species (ROS) levels, resulting in
increased cell susceptibility to DNA damage and levels of the DNA sensor and
repair gene, Gadd45α, and these phenotypes can be rescued by restoring KRIT1
levels (Goitre et al., 2010, 2014). Goitre et al. further showed that the increased
ROS production in KRIT1-depleted cells resulted from hyperactivated NF-κB and
NADPH oxidase signaling and increased Nox4 expression (Goitre et al., 2017).
Importantly, avenanthramide I, an antioxidant and inhibitor of NF-κB signaling,
rescued the defects in barrier function seen in KRIT1 deficient cells (Goitre et al.,
2017). Altogether, these studies point to a model where KRIT1 limits the
accumulation of intracellular oxidants and prevents oxidative stress-mediated
cellular dysfunction and DNA damage by regulating antioxidant proteins. While
most studies link KRIT1 to oxidative stress, CCM2 loss of function in endothelial
cells also induces increased ROS and decreases FoxO1 expression (Gibson et
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al., 2015). CCM3 further plays a role in protecting cells from oxidative stress by
relocating the GCKIII kinase Mst4 to phosphorylate ezrin/radixin/moesin proteins
(Fidalgo, 2010), further highlighting the protective role of the CCM proteins against
oxidative stress-induced CCM pathogenesis.

1.4.2: Inflammation
The CCM proteins and their interacting protein partners regulate endothelial cell
junctional stability and may protect against inflammation. When these proteins are
lost, destabilization of endothelial cell junctions leads to fluid flux across the
endothelial barrier, causing edema (Lee and Liles, 2011). The loss of cell-cell
contacts further exposes the vascular basement membrane, predisposing the
vasculature to constant low-level inflammation (Mackel et al., 1982). Similarly,
while KRIT1 heterozygous mice typically appear phenotypically normal, they
display a greater outflux of fluid, and consequently develop more severe reactions
to inflammatory stimuli (Corr et al., 2012). At the molecular level, partial loss of the
CCM proteins can increase intracellular ROS levels and oxidative stress, leading
to upregulation of inflammatory factors such as NF-κB, AP-1, PPAR-γ and release
of cytokines and chemokines (Corr et al., 2012). Furthermore, many of the
downstream CCM signaling proteins are involved in the inflammatory response.
For example, MEKK3 is regulated by ROS and is part of the NF-κB regulatory
machinery downstream of proinflammatory Toll-like receptors and TNF receptors
(Qin et al., 2006), although it is unclear if this effect is directly linked to signaling of
the CCM protein complex or other MEKK3 signaling pathways. Both KLF2 and
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KLF4 are tightly associated with endothelial redox and inflammatory balance
(Hamik and Jain, 2012). Also, the KRIT1:Rap1 interaction has been reported to
stabilize cell junctions in response to thrombin and acute lung injury, thus
repressing the inflammatory process (Glading et al., 2007). In addition, CCM
lesions accumulate inflammatory cells, including mast cells, T cells and B cells,
neutrophils, and macrophages (Hagiwara et al., 1999; Shi et al., 2007). Notably,
Shi et al. have shown that B-cell depletion reduces the progression of CCM-like
lesions in vivo, suggesting that inflammation contributes to the progression of CCM
and that reversing this can be a potential CCM disease treatment (Shi et al., 2016).
The anti-inflammatory drugs sulindac sulfide and sulindac sulfone can also
significantly reduce CCM lesion genesis in endothelial Ccm3-deficient mice (Bravi
et al., 2015). Finally, combined HMG-CoA reductase and prenylation inhibition may
be a potential treatment option for CCM disease and have anti-inflammatory
effects (Nishimura et al., 2017). Altogether, these studies report various CCM
relevant pathways that trigger inflammation and highlight signs of inflammation in
CCM disease models.

1.4.3: Angiogenesis
The CCM proteins are key negative regulators of angiogenesis and are required
for vascular development. In endothelial cells, altering KRIT1, CCM2, or CCM3
levels impacts endothelial cell network formation and sprouting (Whitehead et al.,
2009; Liu et al., 2010; Wüstehube et al., 2010; Zhu et al., 2010; Schleider et al.,
2011a). In zebrafish, loss of kri-1 or ccm-2 results in increased sprouting, failed
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vessel lumenization, and a dilated heart phenotype (Hogan et al., 2008; Whitehead
et al., 2009; Liu et al., 2010). Similarly, knockout of ccm-3 in zebrafish results in
malformation and dilation of newly formed cerebral vessels (Schleider et al.,
2011a). In murine models, global knockout of Krit1, Ccm2, and Ccm3 results in
embryonic lethality with severe vascular defects (Whitehead et al., 2004; Chan et
al., 2011). Additionally, acute inducible endothelial specific postnatal day 1 deletion
of Krit1, Ccm2, or Ccm3 in mice results in cerebellar and retina lesions resembling
those in human CCM patients (Boulday et al., 2011). The Ccm2 acute model
demonstrates lesion development that is restricted to the vascular bed and during
a time frame of intense angiogenesis (Boulday et al., 2011). Furthermore, CCM
lesions display increased expression of several proangiogenic growth factors like
VEGF, PDGF, and TGF-β (Jung et al., 2003; Maiuri et al., 2006; Abe et al., 2009;
Yildirim et al., 2010). Additionally, both Krit1 and Ccm3 deficient animals exhibit
activation of TGFβ/BMP signaling downstream of β-catenin, which promotes
EndMT, resulting in altered endothelial polarity and abnormal vessel formation
(Lampugnani et al., 2010; Maddaluno et al., 2013). Altogether, these studies
support the role of endothelial CCM proteins and their downstream angiogenic
factors in proper angiogenesis.

1.4.4: Notch signaling
Notch signaling critically suppresses sprouting angiogenesis, and loss of Notch
ligand Dll4 or receptor Notch1 in mice leads to a tip cell-rich, tortuously branched
vessel network with impaired function (Schulz et al., 2015). Increased levels of
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KRIT1 upregulate key components of Notch signaling, including HEY1 and Dll4
(Wustehube, 2010). On the other hand, decreased KRIT1 expression results in
reduced Dll4 and other Notch dependent genes, resulting in increased angiogenic
sprouting (Schulz, 2015). Furthermore, loss of CCM3 in endothelial cells results in
significant downregulation of Notch activity including Dll4, Notch4, HEY2, and
HES1 levels (You et al., 2013). Importantly, treatment with recombinant Dll4
reversed the impairment of Notch signaling resulting from CCM3 silencing (You,
2013). Currently, CCM2 is yet to be linked to Notch signaling, but it is conceivable
that loss of all three CCM proteins individually affect this pathway and contribute
to CCM pathogenesis as they stabilize each other.

1.4.5: EndMT
EndMT is the acquisition of mesenchymal and stem cell like characteristics by
endothelial cells. At the cellular level, EndMT results in dismantled cell-cell
junctions, loss of cell polarity, cytoskeletal modifications, and increased cell
proliferation and motility (Dejana et al., 2017). KRIT1 or CCM3 null endothelial cells
lining CCM lesions exhibit the EndMT phenotypic switch, resulting in formation of
the enlarged and dysfunctional vessel lumens characteristic of CCMs (Maddaluno
et al., 2013; Bravi et al., 2015). Indeed, EndMT likely contributes to dysregulated
angiogenesis as evidenced by: 1) the EndMT inducing transcription factor Slug1
stimulates vessel sprouting (Welch-Reardon et al., 2014), 2) transforming growth
factor-β (TGF-β), which is activated during EndMT and shear stress, is a
proangiogenic cytokine that induces angiogenic sprouting (Otrock et al., 2007),
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and 3) hyperprofileration of cells resulting from EndMT is necessary for sprouting
angiogenesis. Importantly, implicating EndMT’s role in CCM lesion genesis, the
endothelium lining human familial and sporadic CCM malformations showed
upregulation of EndMT markers such as S100a4, αSMA, FN1, CDH2, and ID1
(Dejana et al., 2017; Malinverno et al., 2019).

Upregulated TGF-β and bone morphogenetic protein (BMP) signaling downstream
of the MEKK3-MEK5-ERK5-KLF2/4 pathway mechanistically regulates EndMT.
(Maddaluno et al., 2013; Cunha et al., 2017). As such, inhibitors of the TGF-β and
BMP pathways prevent EndMT in KRIT1 knockout endothelial cells and mice as
shown by reduction in mesenchymal markers (Maddaluno et al., 2013). The
inhibitors also reduce the number and size of vascular malformations in Krit1
deficient mice (Maddaluno et al., 2013). At the molecular level, TGF-β signaling is
mediated by phosphorylation of SMADs, which get translocated to the nucleus and
regulate transcription of target genes. Loss of KRIT1 leads to phosphorylation of
SMAD1 and SMAD3, and inhibiting phospho-SMAD signaling effectively reduces
CCM lesions (Maddaluno et al., 2013), further supporting TGF-β/BMP activation
of EndMT in contributing to CCM lesion formation. EndMT also requires
endogenous upregulation of BMP6 which in turn activates the TGF-β and BMP
signaling pathway. Notably, this BMP6 upregulation occurs specifically in the brain
vasculature, implicating the prevalence of CCMs at this location (Maddaluno et al.,
2013).
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Interestingly, two studies recently reported that clonal expansion from a small
population of CCM3 mutant endothelial cells can give rise to CCMs (Detter et al.,
2018; Malinverno et al., 2019). One of these studies showed that the CCM3-null
cells exhibit EndMT, and can trigger surrounding wildtype cells to convert and
exhibit mesenchymal factors, coinciding with an increase in lesion size in a CCM3
mutant mouse model (Malinverno et al., 2019). This suggests that endothelial cells
residing within CCM lesions have tumor-like properties, and microenvironmental
factors may trigger the EndMT switch in wildtype cells to cause lesion progression
(Malinverno et al., 2019).

1.4.6: Autophagy
Autophagy, a process that sequesters and degrades cellular “trash” to maintain
intracellular homeostasis, was implicated in 2015 to be dysregulated in CCM
pathogenesis (Marchi et al., 2015). Marchi et al. report that loss of KRIT1 in
endothelial cells strongly suppresses autophagy as evidenced by aberrant
accumulation of the autophagy adaptor p62/SQSTM1 and aggresome-like
structures, and increased total mTOR and phospho-ULK1 (a target of mTOR
involved in autophagy regulation) (Marchi et al., 2015). Reduced autophagy is also
seen in CCM2 null endothelial cells, in cells and tissues from endothelial specific
CCM3 knockout mice, and in human CCM lesions (Marchi et al., 2015). Notably,
this defective autophagy results in altered redox signaling and sensitizes cells to
local oxidative stress, as Torin1 (an mTOR inhibitor) treatment, which rescues
aberrant autophagy, also strongly reduced ROS levels (e.g., hydrogen peroxide)
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(Marchi et al., 2015). Furthermore, the suppressed autophagy triggers EndMT
since the higher expression of typical mesenchymal markers (e.g., PAI1, CD44,
and ID1) and reduced expression of endothelial markers (e.g., CDH5 and CD31)
seen in KRIT1 knockout endothelial cells can be reversed upon treatment with
either Torin1 or rapamycin (Marchi et al., 2015). Therefore, many phenotypic
hallmarks of CCM disease can be linked to defective autophagy, including aberrant
ROS production and EndMT, indicating that impaired autophagy may interface with
molecular pathways involved in CCM pathogenesis (Marchi et al., 2016b, 2016a).

1.4.7: Gut-brain axis
A role of the gut microbiome and barrier has recently been linked to brain lesions
in mice CCM models (Tang et al., 2017, 2019). In this model, Gram-negative
bacteria or lipopolysaccharide activates the innate immune Toll-like receptor 4
(TLR4) which consequently activates the MEKK3-MEK5-ERK5-KLF2/4 pathway,
resulting in CCM lesion genesis (Tang et al., 2017). Significantly, genetic or
pharmacologic blockade of TLR4 or broad-spectrum antibiotic treatment
significantly reduces lesion burden in Krit1 endothelial knockout mice (Tang et al.,
2017). When raised germ-free, these Krit1 knockout mice fail to develop lesions
(Tang et al., 2017), showing the role of bacteria and innate immune ligands in
driving CCM lesion genesis. Further supporting a role of the gut in CCM
pathogenesis, Tang et al. later found that disruption of the gut barrier and loss of
CCM3 in the gut epithelium further exacerbates CCM lesion genesis in mice (Tang
et al., 2019). Notably, a single dose of dexamethasone, a glucocorticoid receptor
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agonist that reduces immune responses to LPS and also increases MUC2 (a
component of the mucosal barrier) expression entirely blocked lesion formation in
Krit1 and Ccm3 endothelial specific knockout mice (Tang et al., 2019),
demonstrating the role of both the gut and brain in CCM pathogenesis.

1.4.8: Blood Flow
Shear stress from blood flow on the endothelium critically regulates blood vessel
physiological function and can result in pathological states when aberrant, e.g.,
during CCM lesion genesis. As such, CCM patients and mice develop lesions in
low blood flow regions (Glading et al., 2007; Stockton et al., 2010; Lisowska et al.,
2018; Li et al., 2019). Furthermore, CCM lesions result from upregulation of
KLF2/4, two transcription factors whose activity is regulated by fluid and shear
stress caused by blood flow (Dekker et al., 2002; van Thienen et al., 2006; Nayak
et al., 2011). Other regulators of CCM signaling like RhoA/ROCK (WojciakStothard and Ridley, 2003), β1 integrin (Macek Jilkova et al., 2014; Renz et al.,
2015), and TGF-β (Qi et al., 2011) are also activated by shear stress. Notably,
KRIT1 deficient endothelial cell monolayers exposed to laminar shear stress fail to
align to flow (Mleynek et al., 2014). Loss of kri-1 in the zebrafish also phenocopies
loss of blood flow by exhibiting hypersprouting and caudal vein plexus dilatation,
further supporting that failed endothelial flow response may be a contributing
mechanism for KRIT1 lesion development (Mleynek et al., 2014). Two recent
studies additionally link blood flow as being protective against CCM lesion genesis
(Li et al., 2019; Rödel et al., 2019). First, similar to that reported by Mleynek et al.,
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a different kri-1 mutant zebrafish model causes massively dilated hearts that fail to
produce blood flow (Rödel et al., 2019). Blood flow can be reestablished by
reexpressing KRIT1, consequently rescuing heart morphology and function and
proper vascular development throughout embryogenesis (Rödel et al., 2019).
Second, in CCM2 silenced endothelial cells, RNA-seq profiling showed
upregulation of CCM pathway genes like ROCK1/2, TGFB2, TGFBR1, MYCBP,
ITGB1 and AKT3 only under low shear stress conditions (Li et al., 2019).
Furthermore, loss of CCM2 in endothelial cells resulted in induced RhoA/ROCK
activity, actin reorganization, junction disruption, and oxidative stress that was all
dependent on low flow (Li et al., 2019). Combined these data suggest that blood
flow regulates key CCM-relevant pathways to prevent the cardiovascular
abnormalities seen in CCM patients.

1.4.9: Crosstalk among CCM pathways
Loss of KRIT1, CCM2, or CCM3 perturbs the various large-scale processes
described above that contribute to CCM pathogenesis. Table 1 summarizes the
studies in which loss of KRIT1, CCM2, or CCM3 contributes to the dysregulation
of these processes. In some processes such as angiogenesis and ROS
accumulation, studies in cultured cells, animal models, and human CCM lesions
rigorously support their dysregulation in contributing to CCM pathogenesis.
However, for other processes, such as autophagy and gut barrier and gut
microbiome in CCM signaling, minimal studies (albeit convincing) were performed
and our understanding of the pathway would benefit from further examination in
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different experimental settings and animal models. In other processes such as
blood flow and Notch signaling, their roles in CCM signaling has not been tested
upon loss of each of the three CCM proteins. This calls into question whether loss
of the proteins lead to different mechanisms, and further investigation into the
effect of loss of each CCM protein is required.
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Process
Angiogenesis

Flow
ROS

Inflammation
EndMT

Autophagy
Notch signaling
Gut barrier and
gut microbiome

Upon loss of CCM Attributed to loss of CCM protein
proteins
Increased
KRIT, CCM2, CCM3 (Whitehead et al.,
2009; Liu et al., 2010; Wüstehube et al.,
2010; Zhu et al., 2010; Schleider et al.,
2011a)
Decreased
KRIT1 (Mleynek et al., 2014; Rödel et al.,
2019)
Increased
KRIT1 (Goitre et al., 2010, 2014, 2017),
CCM2 (Gibson et al., 2015), CCM3
(Fidalgo et al., 2010)
Increased
KRIT1 (Goitre et al., 2010, 2014), CCM3
(Shi et al., 2016)
Increased
KRIT1 (Maddaluno et al., 2013), CCM3
(Bravi et al., 2015; Malinverno et al.,
2019)
Decreased
KRIT1, CCM2, CCM3 (Marchi et al.,
2015)
Decreased
KRIT1 (Wüstehube et al., 2010; Schulz
et al., 2015), CCM3 (You et al., 2013)
Weakened and
KRIT1, CCM3 (Tang et al., 2017, 2019)
increased

Table 1: Summarization of how loss of CCM proteins contribute to
dysregulation of processes underlying CCM pathogenesis.
Loss of the CCM proteins results in perturbation of large-scale processes that
contribute to CCM pathogenesis.
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No single model encapsulates how loss of KRIT1, CCM2, and CCM3 impacts
various molecular players and pathways, which then feeds into large-scale
processes because of the vast number of molecular players involved, parallel
routes, and interplay of pathways leading to CCM pathogenesis. Further lending
complexity to the model, each of these protein pathways impact other signaling
processes that may not be directly relevant to CCM signaling. Here, I present a
simplified model that highlights key large-scale processes that contribute to CCM
pathogenesis and the major protein pathways that underlie them (Fig. 1.7).

The large-scale phenotypic changes seen in CCM pathogenesis can result from:
1) a direct loss of the three CCM proteins (i.e., KRIT1, CCM2, CCM3), 2) key
dysregulated pathways resulting from loss of the CCM proteins (e.g., MEKK3,
KLF2/4, Rap1), and/or 3) indirect downstream proteins (e.g., TGF-β/BMP, VEGF,
eNOS). Here, I will relate the key protein pathways underlying CCM signaling to
the large-scale processes they influence (Fig. 1.7). First, hyperactivation of the
MEKK3-MEK5-ERK5-KLF2/4 pathway and its downstream factors result in
angiogenesis, oxidative stress, EndMT, inflammation, and dysregulated flow
(Sangwung et al.; van Thienen et al., 2006; Nayak et al., 2011; Alaiti et al., 2012;
Maddaluno et al., 2013, 2013; Jha and Das, 2017; Sweet et al., 2018). For
example, downstream of KLF2/4, elevated TM and downregulated TSP1 levels
impact angiogenesis and junctional stability (Good et al., 1990; Lopez-Ramirez et
al., 2017, 2019; Wu et al., 2017). Additionally, elevated KLF2/4 levels activate
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TGF-β/BMP signaling, triggering EndMT (Maddaluno et al., 2013; Cuttano et al.,
2016; Ma et al., 2020). On the other hand, perturbed signaling of RhoA/ROCK,
Cdc42, ICAP1, β1 integrin, and other junctional proteins all impact blood vessel
development, angiogenesis, and/or blood flow through regulating cell-cell junction
stability or the cytoskeleton (Bayless and Davis, 2002; Rikitake Yoshiyuki et al.,
2005; Carlson et al., 2008; Tanjore et al., 2008; Whitehead et al., 2009; Brütsch et
al., 2010; Nunes et al., 2010; Faurobert et al., 2013; Castro et al., 2019; Henning
et al., 2019).

Once perturbation in any of these large-scale processes occurs, this triggers
additional molecular pathways either directly or indirectly related to CCM signaling
pathways, which feeds back onto other large-scale processes. While there is a
clear interplay between some of these processes (e.g., angiogenesis and Notch
signaling), some are less directly related (e.g., autophagy and angiogenesis).
Figure 1.7 highlights the established relationships between large-scale processes
leading to CCM pathology and the underlying molecular pathways. Some notable
links include: first, there is a well-established link between angiogenesis and Notch
signaling in that proteins involved in Notch signaling suppresses angiogenesis and
tip sprouting (Siekmann and Lawson, 2007; Hasan et al., 2017; Pitulescu et al.,
2017). Second, disturbed flow patterns can also lead to inflammation through
inducing inflammatory activation of the endothelium as well as oxidative stress
through inducing activation of the NADPH oxidases to promote generation of ROS
(Baeyens et al.; Nigro et al., 2010; Chiu and Chien, 2011). Third, shear stress,
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inflammation, and oxidative stress have all been reported to be angiogenic through
destabilizing endothelial cell-cell junctions and increasing vascular permeability
(Imhof and Aurrand-Lions, 2006; Granger and Senchenkova, 2010; Song and
Munn, 2011; Galie et al., 2014; Kim and Byzova, 2014; Retta and Glading, 2016;
Aguilar-Cazares et al., 2019). Furthermore, autophagic dysfunctions can also be
linked to hallmarks of CCM disease by enhancing oxidative stress and EndMT
(Marchi et al., 2015, 2016b). The full schematic and interplay of processes is
depicted in Figure 1.7.
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Figure 1.7: Model showing interplay of loss of the CCM proteins, key protein
pathways, and large-scale processes.
Loss of KRIT1, CCM2, and/or CCM3 leads to dysregulated downstream signaling
pathways, which influence large-scale processes.
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1.5: Subcellular Localization of the CCM Proteins
The ability of CCM proteins to influence specific signaling pathways depends on
their subcellular localization, and cell compartmentalization can provide one
method of regulating their functions. Thus, in addition to characterizing CCM
protein interactions and signaling pathways, there have been recent efforts to
understand CCM protein localization.

1.5.1: KRIT1 localization
KRIT1 can localize to microtubules (Gunel et al., 2002; Béraud-Dufour et al.,
2007), the cell membrane (Béraud-Dufour et al., 2007; Glading et al., 2007;
Glading and Ginsberg, 2010), and the nucleus (Liu et al., 2013; Marzo et al., 2014;
Draheim et al., 2016; Su et al., 2020). Mostly through its N-terminal NLS, KRIT1
preferentially binds microtubule plus ends, suggesting a potential role in
microtubule targeting (Gunel et al., 2002; Béraud-Dufour et al., 2007). In addition,
Rap1 binding to KRIT1 can inhibit KRIT1 binding to microtubules and can recruit
KRIT1 to the membrane, suggesting that microtubules may serve as tracks to allow
KRIT1 to localize to the membrane where it functions to stabilize cell-cell junctions
(Béraud-Dufour et al., 2007; Glading et al., 2007). At the membrane, KRIT1 and
Rap1 further associate with binding partners such as β-catenin, Rasip1, HEG1,
and VE-cadherin to maintain proper junctional stability and vasculature (Glading
et al., 2007; Glading and Ginsberg, 2010; Gingras et al., 2013; de Kreuk et al.,
2016).
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ICAP1 can also inhibit KRIT1 binding to microtubules and a ternary
ICAP1/KRIT1/Rap1 complex exists in vitro, suggesting that this complex may play
an important role at the membrane. Interesting, both KRIT1 and ICAP1 have
nuclear localizations (Fournier et al., 2005a; Glading et al., 2007; Liu et al., 2013;
Draheim et al., 2016; Su et al., 2020), and ICAP1 directs KRIT1 to the nucleus
dependent on ICAP1’s NLS (Draheim et al., 2016; Su et al., 2020). The nuclear
roles of KRIT1 and ICAP1 are yet to be determined. However, nuclear KRIT1
localizes to perichromatin fibrils that are sites of active transcription shown by
transmission electron microscopy (Marzo et al., 2014) and our group has shown
that KRIT1 binds DNA through its Nudix domain (unpublished data). Meanwhile,
nuclear ICAP1 potentially activates c-Myc transcription since it has been reported
to bind the MYC promoter in vitro (Fournier et al., 2002, 2005a). The authors
suggest that in doing so, nuclear ICAP1 controls cell proliferation since nuclear
overexpressed ICAP1 results in increased cell growth (Fournier et al., 2002,
2005a). Alternatively, ICAP1’s main nuclear function may simply be to target
KRIT1 to the nucleus. As such, ICAP1’s small size and lack of catalytic activity
suggests its role as a scaffolding protein.

KRIT1 has also been reported at intracellular vesicles. Sorting nexin 17 (SNX17),
a non-self-assembling and a PtdIns(3)P binding protein, interacts with KRIT1 and
partially localizes KRIT1 to intracellular vesicles (Czubayko et al., 2006). SNX17
binds to KRIT1’s N-terminal region (Czubayko et al., 2006), suggesting that SNX17
may compete with ICAP1 binding. However, it is unclear what KRIT1’s role is in
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intracellular vesicles and what the SNX17:KRIT1 interaction may mean. To
summarize, while KRIT1 localizes to various compartments, besides its presumed
membrane role in stabilizing cell-cell junctions to prevent the leaky vasculature
seen in CCM lesions, what KRIT1 is doing at microtubules, the nucleus, and
intracellular vesicles and how this relates to CCM pathogenesis is unclear and
requires further elucidation.

1.5.2: CCM2 localization
The KRIT1:CCM2 interaction is well-established and structurally mapped, and the
proteins stabilize each other (Zawistowski, 2005; Faurobert et al., 2013; Liu et al.,
2013; Fisher et al., 2015b). CCM2 is thought to drive KRIT1 to the cytoplasm or
membrane since KRIT1 changes from diffusely-localized to cytoplasmic-localized
upon addition of CCM2, which by itself is cytoplasmic-localized (Zawistowski,
2005). ICAP1, KRIT1, and CCM2 can also exist in a ternary complex with ICAP1’s
PTB domain binding KRIT1’s 1st NPxY motif and CCM2’s PTB domain binding
KRIT1’s 3rd and/or potentially 2nd NPxF motifs (Zawistowski, 2005; Liu and
Boggon, 2013; Liu et al., 2013; Fisher et al., 2015b) (Fig. 1.1) This suggests that
ICAP1 and CCM2 may function as scaffold proteins to localize KRIT1 to either the
nucleus (when KRIT1 is bound to ICAP1) or the cytoplasm (when KRIT1 is bound
to CCM2). It is also possible that the ICAP1/KRIT1/CCM2 ternary complex can
shuttle between the nucleus and the cytoplasm to carry out specific subcellular
compartmental functions. It is unknown what triggers changes in the localization
of this complex.
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In addition to binding KRIT1, CCM2 binds MEKK3. MEKK3 is reported to localize
CCM2 to the peri-plasma membrane as co-expression of CCM2 binding defective
MEKK3 and wildtype CCM2 results in localization at the membrane and cytosol,
respectively (Fisher et al., 2015a). This suggests that the CCM2:MEKK3 binding
interaction is necessary for CCM2’s proper localization to the membrane. A ternary
complex between KRIT1, CCM2 or CCM2L, and MEKK3 can form in cells (Fig.
1.8), but the significance and localization of this complex have yet to be explored
(Zawistowski, 2005; Cullere et al., 2015). For example, while MEKK3-MEK5-ERK5
signaling is hyperactivated in KRIT1 null cells and animals (Zhou et al., 2016b), it
is unclear if direct KRIT1 binding to CCM2 or CCM2L is necessary for CCM2 or
CCM2L to inhibit MEKK3 activity.
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Fig. 1.8: Domain architecture of KRIT1/CCM2/MEKK3 ternary complex.
KRIT1 comprises a Nudix domain, three NPx(Y/F) motifs, an ankyrin repeat
domain, and a FERM domain. CCM2 comprises a PTB domain, a LD-like motif,
and a HHD. MEKK3 comprises a helix, a Phox/Bem1p (PB1) domain, and a kinase
domain. The 3rd or potentially the 2nd NPxF motifs of KRIT1 bind to the PTB domain
of CCM2, while the HHD of CCM2 binds the PB1 domain of CCM3.
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1.5.3: CCM3 localization
CCM3 can localize to the Golgi apparatus (Fidalgo et al., 2010; Kean et al., 2011)
and cell membranes (Dibble et al., 2010; He et al., 2010b), and seems to carry out
functions at these locations independent of its binding to CCM2. For instance,
unlike CCM2 or KRIT1, CCM3 primarily localizes to the Golgi where it co-localizes
with Golgi protein markers (Fidalgo et al., 2010). Importantly, at the Golgi, CCM3
can bind members of the STRIPAK complex including the GCKIII kinases SOK1,
MST3, MST4, and striatins, together carrying out CCM3’s functions in Golgi
repositioning, assembly, and cell migration (Fidalgo et al., 2010; Kean et al., 2011).
Interestingly, depletion of CCM3 causes localization of MST4 to the Golgi whereas
depletion of striatins prevents MST4’s Golgi localization, suggesting CCM3
promotes the cytosolic localization of MST4 (Kean et al., 2011). It is not fully clear
how the different localizations of CCM3 and its interacting partners affect their roles
in Golgi-dependent processes.

Additionally, CCM3 weakly associates with active VEGFR2 at cell membranes in
basal resting conditions (He et al., 2010b). Upon VEGF stimulation, the
CCM2:VEGFR2 interaction is strengthened, presumably activating downstream
vascular pathways (e.g., phosphatidylinositol-3-kinase (PI3K) and AKT). This
suggests a role for CCM2 in proper VEGFR2 signaling and vascular development
(He et al., 2010b). Interestingly, CCM2 also directly binds phosphatidylinositol3,4,5-trisphosphate (PtdIns(3,4,5)P3) and co-localizes at the membrane with
constitutively active PI3K, the enzyme that catalyzes the formation of
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PtdIns(3,4,5)P3 (Dibble et al., 2010). Because VEGF is known to activate PI3K
(Jiang and Liu, 2009), this suggests a combined model in which CCM3 interacts
with activated VEGFR2 following VEGF treatment, thus activating PI3K to form
PtdIns(3,4,5)P3 which can then bind CCM3 to regulate vascular processes (Dibble
et al., 2010). CCM2 and PtdIns(3,4,5)P3 appear to bind CCM3 at the same site
(Dibble et al., 2010; Draheim et al., 2015), suggesting an equilibrium between
these two complexes; however, the significance of this is still unknown. Thus,
CCM3 localizes with partners at the Golgi and membrane to support its functions
there, yet several questions remain including: when and why does CCM3 bind its
different interacting partners?, how does perturbing these interactions trigger CCM
pathogenesis?, and what triggers CCM3 to localize to its different subcellular
compartments?. It is worth noting that CCM3 appears to uniquely localize at the
Golgi and binds proteins distinct from KRIT1 and CCM2, supporting that CCM3
has unique functions.

1.5.4: Signals that Regulate CCM Protein Localization
As described above, the functions of the CCM proteins are likely to be regulated
by localization to specific subcellular compartments. However, the signals that
control their localization or redistribution are largely unknown. As detailed in
Chapter 2, part of my dissertation research focused on mechanisms controlling
localization of ICAP1, and hence KRIT1, to the nucleus. Briefly, we find that
phosphorylation of ICAP1 at Ser10, adjacent to the NLS, or to a lesser extent at
Ser25, inhibits nuclear accumulation of ICAP1. We further show that Ser10 can be
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phosphorylated by active PAK4 and that this inhibits nuclear accumulation of
ICAP1 and the ICAP1:KRIT1 complex.

Another signal known to trigger localization changes in the CCM proteins is VEGF.
Along with stabilizing the VEGFR2:CCM3 interaction, VEGF can additionally
trigger their internalization from the membrane to intracellular vesicles (He et al.,
2010b). It is unclear why VEGF can trigger endocytosis of the VEGFR2:CCM3
complex. However, a CCM3 human disease mutant containing only the N-terminal
region when co-expressed with VEGFR2 is also internalized even in the absence
of VEGF, suggesting that the C-terminal region of CCM3 stabilizes the
CCM3:VEGFR2 complex at the membrane (He et al., 2010b). However, in the
event of abnormal amounts of CCM3 or mutant CCM3, the CCM3:VEGFR2
complex may be endocytosed, thus downregulating receptor signaling (or enabling
signaling from endosomes).

Additionally, sorbitol has been shown to regulate the localizations of KRIT1, CCM2
and MEKK3 (Uhlik et al., 2003; Zawistowski, 2005). RNAi knockdown
demonstrates that MEKK3 or CCM2 are necessary for p38 activation in response
to sorbitol-induced hyperosmolarity, and sorbitol drives CCM2 and MEKK3
localization from the cytosol to actin ruffles (Uhlik et al., 2003). This indicates that
CCM2 and MEKK3 redistribution to membrane ruffles may be required for p38
activation and proper stress response (Uhlik et al., 2003). In a separate study,
sorbitol triggers localization of KRIT1 and CCM2 from the cytosol to the cell
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periphery and strengthened their binding interaction, perhaps suggesting that the
KRIT1:CCM2 interaction may also be necessary for p38 activation in response to
stress stimuli (Zawistowski, 2005). It would be interesting to explore whether the
membrane-localization of KRIT1, CCM2, and MEKK3 is perturbed during CCM
pathogenesis (similar to inability to properly activate p38 if KRIT1, CCM2, and
MEKK3 are not present at membranes) and if this contributes to the characteristic
hyperactivated MEKK3/ERK5/KLF2/4 signaling seen in CCM lesions. Likewise,
the various binding interactions and localizations of CCM2 could rationalize its
apparent function as both an activator of the p38 pathway and inhibitor of the
MEK5-ERK5 kinase cascade.

1.6: Treatment for CCM Disease and Outlook
There are scarce pharmacological treatments for CCM disease with the only being
antiepileptic medications for the subset of CCM patients exhibiting seizures
(Kondziolka et al., 1995) and up to 40% of these patients become resistant to the
medication (Chohan et al., 2019). Current methods to monitor or treat CCMs
involve observation and conservative management most commonly through MRI
screening, surgery, radiosurgery, and stereotactic laser ablation (Hasegawa et al.,
2002; Akers et al., 2017; Willie et al., 2019; Caton and Shenoy, 2020). The most
effective method of treatment remains surgery; however, this procedure is risky
since remnants may rupture if the lesion is not completely removed (Gross et al.,
2013; Chen et al., 2017). Furthermore, surgical options are limited by lesion
accessibility and are associated with significant rates of morbidity and mortality.
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After CCM surgical resection, there is an overall risk of death or nonfatal stroke of
6%, exceeding the natural risk of a CCM that has never bled (2.4% over 5 years)
(Poorthuis et al., 2013), indicating that conservative management by MRIs is a
sufficient treatment option for mild CCM cases. Surgical resection in the case of
easily accessible ICHs may be a viable option. However for deep-seated lesions,
the risk of morbidity during surgery is 18%, and for brainstem lesions, surgery
results in postoperative morbidity in 45% of cases (Pasqualin et al., 2014).

Given the current treatment options, there are no effective approaches to delay
lesion growth and formation (Brunereau et al., 2000), which can reach a rate of 2.7
new lesions per patient per year in the most severe of CCM3 gene mutant cases
(Shenkar et al., 2015). The lack of effective treatments motivates a higher
understanding of the dysregulated cellular pathways involved in CCM signaling to
develop therapeutics.

Several rationally designed preclinical pharmacological candidates are being
pursued to target CCM lesions; however, only a few remain in clinical trials
(Chohan et al., 2019). Candidates typically are inhibitors targeting proteins
upregulated as a result of loss of KRIT1, CCM2, and/or CCM3 in CCM lesions. For
example, the anti-VEGF-A antibody bevacizumab (Aguilera et al., 2010) and the
β-adrenergic blocker and antiangiogenic agent propranolol are among the few
clinical trial candidates (Zabramski et al., 2016; Zhu et al., 2018). Additionally,
some promising preclinical inhibitors target ERK (Wüstehube et al., 2010), EphB4
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kinase (You et al., 2017), and toll-like receptor 4 (Tang et al., 2017) that are all
components of the MEKK3-KLF2/4 axis, as well as fasudil (Stockton et al., 2010;
McDonald et al., 2012), atorvastatin (Polster et al., 2019), and simvastatin
(Whitehead et al., 2004) which can target the RhoA/ROCK axis. Importantly,
atorvastatin is part of an enrolling phase I/II clinical trial (Polster et al., 2019).
Recently, a ROCK2 inhibitor has also been reported to reduce CCM lesion burden
in murine models (McKerracher et al., 2020). It is worth noting that statins inhibit
HMG-CoA reductase, and while they may experimentally inhibit ROCK activity, it
remains to be determined whether statins will be clinically effective in reducing
CCM lesions in human patients (Li and Whitehead, 2010).

While the majority of pharmacological approaches have been rationally designed
molecular studies, recent unbiased small-molecule suppression screens may hold
promise. For instance, a screen using repurposed drug compounds in CCM2
deficient endothelial cells revealed vitamin D3 (a physiological compound with
autophagy-inducing (Høyer-Hansen et al., 2010) and antioxidant properties
(Wiseman, 1993)) and tempol (a scavenger of superoxide), which were both later
validated to reduce lesion burden by ~50% in a mouse model of CCM disease
(Gibson et al., 2015; Malinverno et al., 2019). Next, a screen using 5,268
compounds applied to CCM mutant C. elegans, zebrafish, mouse, or human
endothelial cells, identified dozens of new and already identified candidates
involved in angiogenesis, innate immunity, the oxidative stress/redox system, etc.
(Otten et al., 2018). Notably, the study identified indirubin‐3‐monoxime, a drug
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originally derived from traditional Chinese medicine, to rescue the CCM phenotype
in kri-1 deficient zebrafish, CCM2 or CCM3-depleted HUVECs, and Ccm2 or Ccm3
mutant mice through targeting the MEKK3-KLF2/4 pathway (Otten et al., 2018).
Finally, Nishimura et al. used a high-throughput screen and identified that
fluvastatin and zoledronate reversed neural and vascular abnormalities resulting
from CCM3 loss (Nishimura et al., 2017).

In summary, there has been rapid recent progress in understanding CCM protein
signaling networks, how they impact cellular behavior, and their intersections with
physiological processes. While these advances have yet to be translated into
approved therapeutics for CCM disease, both targeted and unbiased approaches,
in combination with further investigation of the molecular processes underlying
CCM disease, offer hope for pharmacological intervention in this potentially
devastating disease.

1.7: Thesis Objectives
Currently, while many molecular pathways and processes of CCM signaling have
been elucidated, how they interplay and result in CCM pathogenesis when
perturbed remains unclear. Furthermore, while it appears that the CCM proteins
and their partners carry out their functions dependent on their subcellular
localization, what regulates their localization and their functions at distinct
localizations require further study. Although some biochemical triggers have been
identified (e.g., VEGF for VEGFR2 and CCM2 and sorbitol for CCM2, MEKK3, and
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KRIT1), little is known about their underlying mechanisms nor about triggers
controlling other CCM protein complexes. My studies (detailed in Chapter 2) add
to this field of knowledge by identifying a mechanism that regulates localization of
ICAP1 and the ICAP1:KRIT1 complex, presumably impacting their currently
unknown nuclear functions.

In Chapter 2, I identify serine phosphorylation in preventing nuclear accumulation
of ICAP1 and the ICAP1/KRIT1 complex. I demonstrate using quantitative
microscopy that phosphorylation mimicking mutations at Ser10, or to a lesser
extent at Ser25, within this N-terminal region inhibits ICAP1 nuclear accumulation.
I further demonstrate that p21-activated kinase 4 (PAK4) can phosphorylate ICAP1
at Ser10 in vitro and in cultured cells, and that active PAK4 inhibits ICAP1 nuclear
accumulation in a Ser10-dependent manner. Finally, I show that ICAP1
phosphorylation controls nuclear localization of the ICAP1/KRIT1 complex.
Therefore, serine phosphorylation of ICAP1 within its N-terminal region can
prevent nuclear accumulation of ICAP1. This work is the first to identify a
biochemical mechanism to regulate localization of ICAP1 and the ICAP1:KRIT1
complex, potentially influencing their functions in CCM signaling and vascular
development.

In the appendix, I investigate the KRIT1:CCM2 binding stoichiometry and
interaction, and how these impact relevant phenotypes including: MEKK3-MEK5ERK5-KLF2/4 signaling, cell growth, endothelial network formation, and
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KRIT1:CCM2 protein stability. I have preliminarily found that knockdown of KRIT1
or CCM2 in EA.hy926 cells upregulates KFL2 and KLF4 mRNA levels, impairs cell
growth, and impairs network formation. Further work is needed to test whether
rescue with wildtype or binding defective KRIT1 or CCM2 rescues these
phenotypes.
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Chapter 2: Serine phosphorylation of the small phosphoprotein ICAP1
inhibits its nuclear accumulation
2.1 Introduction
ICAP1 is a small phosphoprotein composed of an unstructured N-terminal region
and a C-terminal phosphotyrosine-binding (PTB) domain. It is ubiquitously
expressed and has been implicated in development of bone and the vascular
system (Brütsch et al., 2010; Brunner et al., 2011; Faurobert et al., 2013). ICAP1
inhibits integrin function by competing with integrin activating proteins (Bouvard et
al., 2003; Liu et al., 2013; Millon-Fremillon et al., 2013). This impacts processes
such as focal adhesion assembly, cell adhesion/spreading, and cell migration
(Degani et al., 2002; Bouvard et al., 2003; Millon-Frémillon et al., 2008; Brunner et
al., 2011). However, the exact cellular roles of ICAP1 remain incompletely
understood, and integrin independent ICAP1 functions are suggested by the
identification of additional ICAP1 binding partners (Zhang et al., 2001; Degani et
al., 2002; Fournier et al., 2002, 23; Zawistowski et al., 2002; Stroeken et al., 2006).
Notably, the CCM protein KRIT1 binds tightly to ICAP1 (Zhang et al., 2001;
Zawistowski et al., 2002).

KRIT1 is essential for vascular development and Krit1-null mice die in midgestation with vascular defects such as vascular dilation, impaired arterial identity,
and narrowing of branchial arch arteries and rostral dorsal aorta (Whitehead et al.,
2004). Importantly, KRIT1 was the first gene linked to CCM disease, is the most
commonly mutated, and is present in >40% of inherited cases (Kurth et al., 1994;
Marchuk et al., 1995; Cavé-Riant et al., 2002b; Riant et al., 2013). However, the
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molecular mechanisms underlying the roles of KRIT1 in CCM signaling and
vascular processes are not fully resolved. For example, KRIT1 was first identified
as an effector of Rap1 (Serebriiskii et al., 1997), facilitating its function in stabilizing
endothelial cell-cell junctions (Glading et al., 2007; Liu et al., 2011). However,
KRIT1 also binds and stabilizes CCM2 (Zawistowski, 2005; Fisher et al., 2015b)
and ICAP1 (Zhang et al., 2001; Zawistowski et al., 2002; Liu et al., 2013; Draheim
et al., 2016), impacting vascular processes like contractility and angiogenesis
(Stockton et al., 2010; Faurobert et al., 2013; Lisowska et al., 2018).

Binding of the PTB domain of ICAP1 to the first NPxY/F motif of KRIT1 stabilizes
both proteins, preventing their proteasomal degradation (Zawistowski, 2005;
Faurobert et al., 2013). Although ICAP1 mutations have not been linked to CCM
(Faurobert et al., 2013), ICAP1 is important for normal vascular development
(Brütsch et al., 2010; Faurobert et al., 2013), likely in part due to its strong
association with KRIT1. Icap1 null mice display striking vascular abnormalities
including massive dermal bleeding upon dissection and hemorrhagic kidneys due
to increased vessel permeability and dilation of the blood vasculature (Faurobert
et al., 2013, 1). Thus, both KRIT1 and ICAP1 are important for proper vascular
development.

The Boggon lab previously identified an interaction between the ICAP1 PTB
domain and the first KRIT1 NPxY/F motif (Liu et al., 2013), and characterized a
nuclear localization signal (NLS) in the unstructured region of ICAP1 responsible
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for its nuclear accumulation (Draheim et al., 2016). We further showed that the
ICAP1 NLS is the key determinant of nuclear accumulation of KRIT1 and that this
relies on the formation of an ICAP1/KRIT1 complex (Draheim et al., 2016). Thus,
signals that regulate ICAP1 nuclear localization will likely impact KRIT1 localization
and signaling.

Protein phosphorylation is a well-established regulator of nuclear import
(Harreman et al., 2004; Nardozzi et al., 2010). ICAP1 contains 15 phosphorylated
serine residues shortly downstream of its canonical basic NLS identified by mass
spectrometry (Kim et al., 2011), suggesting that phosphorylation at these sites
might impact its localization. Previous studies have implicated phosphorylation of
ICAP1 at threonine 38 in inducing its conformation change to increase its binding
to β1 integrin (Bouvard et al., 1998; Millon-Fremillon et al., 2013). However,
phosphorylation as a method of regulating ICAP1 localization has not been
explored. In this chapter, I discuss how I investigate phosphorylation of ICAP1 in
regulating its nucleocytoplasmic shuttling. I report that phospho-mimicking
mutations at serine 10 and 25, known ICAP1 phosphorylation sites (Kim et al.,
2011), prevent nuclear accumulation of ICAP1 and the ICAP1/KRIT1 complex.
ICAP1 Ser10 lies within a consensus type II p21-activated kinase (PAK)
phosphorylation site sequence. I also demonstrate that activated PAK4 can
phosphorylate ICAP1 at Ser10, preventing the nuclear accumulation of ICAP1 and
consequently

KRIT1.

Therefore,

phosphorylation
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can

govern

the

nucleocytoplasmic distribution of ICAP1 and the ICAP1/KRIT1 complex,
presumably impacting their roles in vascular biology and CCM signaling.

2.2. Materials and Methods
2.2.1: Antibodies/cDNA
Anti-GFP (Rockland, catalogue #600-101-215), anti-ICAP-1 (R&D systems,
catalogue #AF6805), anti-DsRed (Clontech, catalogue #632496), anti-Flag®
(Sigma-Aldrich, catalogue #F1804), and anti-vinculin (VCL, Sigma, V-9131)
antibodies were purchased. Wild-type and mutant ICAP1 (Liu et al., 2013; Draheim
et al., 2016), KRIT1 (Liu et al., 2013; Draheim et al., 2016), and PAK (Morse et al.,
2016) cDNAs previously used for protein expression/purification were subcloned
into pmCherry-C1 (Clontech), pEGFP-C1 (Clontech), and pV1900 3x Flag (gift
from Benjamin Turk, Yale). Additional mutations were introduced by QuikChange
site-directed mutagenesis (Stratagene). Lentiviral ICAP1 and Histone 2B
expression constructs were generated by subcloning into CMV-pLENTI-Hygro
(Addgene). All constructs used were authenticated by DNA sequencing.

2.2.2: Cell Culture
HEK 293T, HeLa, and CHO cells were cultured in Dulbecco modified Eagle
medium containing 9% fetal bovine serum, 1% Sodium Pyruvate, and 1%
nonessential amino acids (Gibco). All lines were confirmed to be mycoplasma free
by testing with MycoAlertTM Mycoplasma Detection Kit (Lonza).
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2.2.3: Lentiviral knockdown and expression
Lentiviruses were produced by co-transfecting packaging vectors psPAX2 (viral
proteins Gag and Rev under the SV40 promoter; Addgene plasmid #12260, a gift
from D. Trono, École Polytechnique Fédérale de Lausanne, Lausanne,
Switzerland) and pMD2.G (viral protein VSV-G expressed under the CMV
promoter; Addgene plasmid #12259, a gift from D. Trono) into HEK 293T cells with
the shRNA construct. Viral supernatant was collected 48 and 72 h after
transfection and filtered with a 0.45-µm filter.

To generate polyclonal knockdown or expression lines, cells were incubated with
viral supernatant and 8 µg/ml polybrene for 24 h. Cell were either analyzed 48-72
h post infection or selected with 50 µg/ml Hygromycin (CMV-pLENTI-Hygro) as
appropriate.

2.2.4: Sample preparation and immunoblotting
Unless otherwise stated, transfected cells were lysed in RIPA buffer (50 mM Tris,
pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS)
containing cOmplete protease inhibitor mixture tablets (Roche) for 30 mins, boiled
in 4X Laemmli Sample Buffer for 5 mins at 95°C, and loaded onto a 12% SDSPAGE gel. Samples were transferred to 0.45 µm nitrocellulose membranes, and
membranes were blocked for >1 hr in 5% milk in TBST. Immunoblotting was
performed with primary antibodies diluted in 5% BSA in TBS-T (1:1000 of α-GFP,
1:1000 of α-DsRed, 1:1000 of α-Flag, 1:10000 of α-Vinculin) fluorescent secondary
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antibodies (IR Dye800 or IR Dye680; LI-COR Biosciences diluted 1:20000 in 5%
BSA in TBS-T) and scanned on the Odyssey CLx infrared imaging system.

2.2.5: Microscopy
CHO cells were transfected with GFP, mCherry and/or V1900 3x Flag expression
vectors using linear polyethylenimine, MW 25,000 (PEI; Polysciences, Inc). 24 hrs
later, cells were plated on coverslips coated with 5 μg/ml fibronectin (SigmaAldrich). 24 hrs after re-plating, cells were fixed in 4% paraformaldehyde in PBS,
pH 7.4 for 15 min, washed with PBS, stained with 1:2000 Alexa Fluor 647
Phalloidin (ThermoFisher) in PMZ-T Buffer for 30 min or with 0.2 µg/mL HCS
CellMask™ Deep Red Stain in PBS following Triton® X-100-permeabilization,
washed with PBS, and mounted using ProLong Diamond with 25 ng/mL DAPI
added (Invitrogen). Images were acquired using Nikon Eclipse Ti-S with a 40X or
100X objective using the µManager acquisition software (Stuurman et al., 2010).
A minimum of 50 cells (from >3 replicates) were analyzed for each singleexpression experiment and a minimum of 75 cells (from >3 replicates) were
analyzed for each double-expression experiment. For live imaging experiments,
cells stably infected with GFP-Histone 2B were plated on glass-bottom dishes
(MatTek) and stained with HCS Cell Mask Deep Red Stain (ThermoFisher) prior
to imaging using a Nikon Ti-2 Eclipse microscope (Nikon; Tokyo, Japan, USA) with
a Prime95B RoHS cMOS Camera (pixel size =110nm) (Photometrics; Tuscon, AZ,
USA). We verified by immunoblot that exogenous proteins were of the expected
size. Quantification of ICAP1/KRIT1 nuclear/cytoplasmic localization was
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performed using CellProfiler 2.1 (Carpenter et al., 2006). Nuclear GFP and/or
mCherry was quantified as the integrated intensity of the fluorophore within the
nucleus, as defined by DAPI staining. The outer boundary of cell was determined
by the Watershed - Image method within CellProfiler 2.1 using the Phalloidin or
HCS CellMask™ fluorescence signal (Carpenter et al., 2006). Data were charted
and statistical analyses were performed using GraphPad Prism.

2.2.6: In vitro kinase assays
Previously used pGEX-6P-1 wt ICAP1 (Liu et al., 2013; Draheim et al., 2016) and
pGEX-6P-1

ICAP1

phosphomutants

(generated

via

QuikChange)

were

transformed in BL21 (DE3) RosettaTM (Novagen) cells and were cultivated at 37°C
to an OD600 of 0.6. ICAP1 expression was induced by 0.1 mM of isopropyl β-D1-thiogalactopyranoside (IPTG) at 16°C for 20 hrs. Cell pellets were then lysed in
50 mM Tris-HCl pH 7.9, 100 mM NaCl, 5% glycerol, 0.1 mM tris(2-carboxyethyl)
phosphine (TCEP) and 1X of cOmpleteTM EDTA free protease inhibitor cocktail
(Roche). GST-ICAP1 was purified from the lysate on Sepharose-4B glutathione
beads. GST-ICAP1 was further purified by size-exclusion chromatography on
SuperdexTM S200 16/600 pg column (GE Healthcare) in 50 mM Tris-HCl pH 8.2,
100 mM NaCl, 5% glycerol, 0.1 mM TCEP and concentrated using Amicon® Ultra4 (Millipore) centrifugal filters. Purified N-terminally hexahistidine-tagged PAK4
catalytic domain prepared as described (Miller et al., 2019) was kindly provided by
Chad Miller (Yale University).
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ICAP1 kinase reactions contained 100 nM kinase and 1 μM purified ICAP1 in
kinase assay buffer (50 mM Tris pH 7.5, 10 mM DTT, 2.5 mM MgCl 2). Reactions
were started by the addition of ATP (10 μM, with 0.20 μCi/μL [γ-33P]ATP),
quenched with 4X Laemmli sample buffer after 30 min incubation at 30°C and
fractionated by 12% acrylamide SDS-PAGE. Gels were dried and radiolabel
incorporation detected by phosphor imaging (Bio Rad Molecular Imager FX Pro
Plus).

2.2.7: Phos-tagTM
CHO cells were co-transfected with GFP or Spot® and mCherry expression
constructs using Lipofectamine® 2000 (ThermoFisher) following manufacturer’s
instructions. 24 hrs later, cells were washed with PBS, scraped, and lysed directly
in plate with RIPA buffer containing 1X of cOmpleteTM EDTA free protease inhibitor
cocktail (Roche) and 1X PhosSTOPTM phosphatase inhibitor cocktail (Roche).
Cells were sheared 5X with a 23g needle, sonicated briefly, and centrifuged at
maximum speed. The supernatant was incubated with GFP-nanotrap (Rothbauer
et al., 2008; Kadry et al., 2018) or Spot®-Trap Agarose (ChromoTek) for 2 hrs at
4°C with rotation. Beads were washed 2X then subjected to lambda protein
phosphatase or mock treatment (LambdaPP, NEB) following manufacturer’s
instructions. 2X Laemmli Sample Buffer was added to beads, boiled for 5 mins,
and loaded onto 12.5% SuperSep Phos-tagTM precast gels (Wako Pure Chemical
Industries, Ltd.). Electrophoresis was performed at 90 V until the bromophenol blue
dye reached the bottom of the gel. Gels were soaked in transfer buffer (25 mM
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Tris, 192 mM glycine, 20% (v/v) MeOH) with 10 mM EDTA for 10 mins, repeating
2x with buffer exchanges. Gels were then soaked in transfer buffer without EDTA
for 10 mins, then transferred to PDVF membranes. After transfer, the membranes
were soaked in TBS-T for 1 h, blocked with 3% BSA in TBS-T for 1 hr, and probed
with α-GFP or α-ICAP-1 antibody in 3% BSA in TBS-T.

2.3 Results
2.3.1: ICAP1 phosphorylation site mutants alter its localization
The largely unstructured N-terminal region of ICAP1 preceding the PTB domain
contains the short NLS as well as 15 serine residues previously shown by mass
spectrometry to be phosphorylated (Kim et al., 2011) (Fig. 2.1A). To investigate
whether phosphorylation of these residues influences ICAP1 nuclear localization,
I generated phospho-mimicking serine to glutamic acid (S/E) and phosphoblocking serine to alanine (S/A) mutations in N-terminally green fluorescent protein
(GFP)-tagged ICAP1 (GFP-ICAP1). I expressed these mutants in CHO cells and
assessed ICAP1 localization by quantitative microscopy. To facilitate examination
of all candidate serine residues, I initially divided residues into 5 groups (i-v; Fig.
2.1A) and generated combination mutants of all residues in a given group. CHO
cells were transfected with GFP, GFP-ICAP1, or GFP-ICAP1 grouped
phosphorylation site mutants, and GFP localization was examined by fluorescence
microscopy. As the Calderwood lab previously reported (Draheim et al., 2016),
wild-type (wt) GFP-ICAP1 predominantly localizes to the nucleus in CHO cells in
a manner dependent on the N-terminal 49 ICAP1 residues containing the NLS
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(Fig. 2.1B). Strikingly, phospho-mimicking mutations in group i (residues 10-14) or
group iii (residues 25, 28-29) resulted in dramatically decreased ICAP1 nuclear
accumulation (Fig. 2.1B). As expression level can impact localization of
recombinant proteins, I attempted to examine cells with comparable GFP signals.
Quantitative analysis of GFP nuclear percentage in multiple images from at least
3 independent experiments using CellProfiler 2.1 (Carpenter et al., 2006) revealed
that on average GFP-ICAP1 was ~65% nuclear while both GFP-ICAP1 SiE and
SiiiE phospho-mimicking mutants were significantly less nuclear at ~38% and
~50%, respectively (Fig. 2.1C). These effects are unlikely to be due to global
effects on ICAP1 folding as the mutations all lie in the N-terminal unstructured
region and even the complete deletion of this N-terminal region does not prevent
the folding of the PTB domain or its interactions with binding partners such as
KRIT1 or integrin (Liu et al., 2011; Draheim et al., 2016). Immunoblotting confirmed
that all GFP-ICAP1 phosphorylation site mutants were expressed at the expected
molecular weights (Fig. 2.1D).
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Figure 2.1: Grouped phospho-mimicking mutants inhibit ICAP1 nuclear
localization.
(A) Schematic of ICAP1 noting the boundaries of the NLS sequence, PTB domain,
and indicating the five groups (i-v) of serine residues that were mutated to glutamic
acid or alanine. (B) Representative images of CHO cells expressing wt GFPtagged ICAP1, or various ICAP1 mutants, fixed 24 hours after plating on fibronectin
and stained with DAPI (to identify nuclei). Bar represents 10 µm. (C) The
percentage of the total integrated whole cell GFP intensity found in the nucleus
was calculated for each cell using CellProfiler2.1. The total number of cells (N) in
each condition from 3 independent experiments is indicated. Boxes represent 2550 and 50-75 percentile, whiskers show the 10-90 percentile, mean is shown as a
dot. Statistical significance was determined by a one-way ANOVA with Fisher’s
LSD test with multiple comparisons, **** indicates p≤0.0001. (D) Representative
immunoblots indicate expression of individual phosphomutants at the expected
size; immunoblotting is against GFP for phosphomutants and Vinculin for loading
control.
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Next, to assess whether a single serine residue from groups i or iii could alter
ICAP1 localization, individual GFP-ICAP1 serine phosphorylation site mutants
were generated, and their nuclear localizations were assessed as described
above. For group i, only the phospho-mimicking S10E mutant reduced ICAP1
nuclear localization, while mutations at Ser11, Ser12, Ser13, or Ser14 had no
significant impact on targeting (Fig. 2.2A,B). Notably, the single GFP-ICAP1 S10E
mutant exhibited a reduction in nuclear localization comparable to that seen in the
SiE grouped mutant (~43% for S10E and ~41% for SiE compared to ~65% for wt
ICAP1; Fig. 2.2B). Furthermore, the phospho-blocking S10A mutation, but not
mutations at Ser11, Ser12, Ser13, Ser14, modestly but significantly enhanced
GFP-ICAP1 nuclear localization (Fig. 2.2A,B). Together, these data indicate that
mutation of S10 modulates ICAP1 nuclear localization.

For individual group iii mutations, only the S25E mutant significantly inhibited GFPICAP1 nuclear localization (~52%) and the inhibition was similar to that seen with
the grouped SiiiE mutant (Fig. 2.2D,E). The phospho-blocking S25A mutation also
enhanced GFP-ICAP1 nuclear targeting (Fig. 2.2D,E), consistent with inhibition of
nuclear accumulation by phosphorylation of serine 25. Immunoblotting was
performed to verify expression and size of all GFP-ICAP1 phosphorylation site
mutants (Fig. 2.2C,F).
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Figure 2.2: Individual phosphomutations at S10 or S25 alter ICAP1 nuclear
localization.
To assess whether single serine mutations alter ICAP1 localization, individual
GFP-ICAP1 serine phospho-mimicking or phospho-blocking mutations from group
i (A-C) or group iii (D-F) were generated and expressed in CHO cells. (A,D)
Representative images of CHO cells expressing GFP-tagged ICAP1 constructs
stained with DAPI (to identify nuclei) 24 hours after plating on fibronectin. Bar
represents 10 µm. (B,E) Percentage of GFP intensity in the nucleus. Boxes
represent 25-50 and 50-75 percentile, whiskers show the 10-90 percentile, +
indicates mean. Results are from 3 independent experiments and the total number
of cells examined (N) is indicated for each condition. **** indicates statistical
significance at p≤0.0001 as determined by a one-way ANOVA with Fisher’s LSD
test with multiple comparisons. (C,F) Representative immunoblots (against antiGFP and anti-Vinculin) indicate expression of individual phosphomutants at the
expected size.
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2.3.2: ICAP1 Ser10 is the major site governing ICAP1 localization
The phosphorylation site mutation analysis implicates both Ser10 and Ser25 in
control of ICAP1 nuclear localization. However, the ICAP1 S10E mutation appears
to inhibit nuclear accumulation more strongly compared to the S25E mutation
(~43% vs ~52%; Fig. 2.2B vs. 2.2E). This difference is also evident in the grouped
phosphomutant constructs, with ICAP1 SiE exhibiting less nuclear accumulation
than ICAP1 SiiiE (Fig. 2.1B,C). Furthermore, this trend is also seen with ICAP1
containing a C-terminal mCherry tag (ICAP1-mCherry), indicating that neither the
fluorescent tag nor its position with respect to ICAP1 account for this result (Fig.
2.3A). Additionally, similar results were also obtained when GFP-ICAP1 constructs
were expressed in HeLa cells (Fig. 2.3B).

To further examine whether Ser10 is the main site governing ICAP1 localization, I
generated C-terminal GFP tagged ICAP1 (ICAP1-GFP) compound (S10A/S25A
and S10E/S25E) and mixed (S10A/S25E and S10E/S25A) phosphorylation site
mutants and examined their localization. As expected, the double S10A/S25A
mutant was strongly nuclear-localized similar to the individual S10A or S25A
mutants (Fig. 2.3C). Furthermore, like the individual S10E mutant, the double
S10E/S25E mutant exhibited only background GFP levels of nuclear staining (Fig.
2.3C). However, despite the presence of the phospho-mimicking S25E mutation,
the mixed S10A/S25E mutant was largely nuclear, comparable to the S10A mutant
or S10A/S25A double mutant (Fig. 2.3C). Likewise, despite the phospho-blocking
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S25A mutation, the mixed S10E/S25A mutant exhibited greatly reduced nuclear
localization (Fig. 2.3C). These data suggest that modifications of Ser10 are the
dominant regulators of ICAP1 nuclear localization. However, Ser25 does influence
ICAP1 localization even in the presence of a phospho-mimicking S10E mutation
since the S10E/S25A mutant was slightly, but statistically significantly, more
nuclear-localized than the S10E/S25E mutant (Fig. 2.3C).
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Figure 2.3: S10 is the major site governing ICAP1 nuclear localization.
CHO cells (A, C) or HeLa cells (B) were transfected with constructs encoding
mCherry, C-terminally mCherry-tagged ICAP1 and phosphomutants (A), or GFP,
N-terminally GFP-tagged ICAP1 and phosphomutants (B), or GFP, C-terminally
tagged ICAP1-GFP and phosphomutants (C). Cells were plated on fibronectin,
fixed 24 hours later and stained with DAPI (to identify nuclei). Nuclear GFP or
mCherry signal was calculated and results from three independent experiments
are displayed in box and whiskers plots. (D) CHO cells stably expressing GFPHistone 2B (to identify nuclei) and transiently transfected with constructs
expressing mCherry or C-terminal mCherry-tagged ICAP1, ICAP1
phosphomutants, or ICAP1 containing mutations in the NLS (ICAP1 KK6,7AA),
were plated on fibronectin-coated glass bottom dishes (MatTek), stained with HCS
CellMask Deep Red Stain (to identify cell boundaries), and imaged live. Nuclear
mCherry signal was calculated in three independent experiments and presented
in box and whiskers plots. In all panels, boxes represent 25-50 and 50-75
percentile, whiskers show the 10-90 percentile, and the mean is shown with a +.
The total number of cells measured in each condition (N) is indicated. Statistical
significance was determined by a one-way ANOVA with Fisher’s LSD test. **
indicates p≤0.01, *** indicates p≤0.001, and **** indicates p≤0.0001.
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To exclude the possibility that fixation artificially increased nuclear ICAP1 levels, I
assessed ICAP1-mCherry localization by live-cell microscopy in cells where the
nucleus was marked with GFP-histone H2B. As shown in Fig. 2.3D and Fig. S2D,
data from live cells were comparable to those in fixed cells and supported the
importance of Ser10 and Ser25. Notably, localization of phospho-mimetic ICAP1
S10E/S25E was equivalent to ICAP1 containing mutations inactivating its NLS
(ICAP1 K6A/K7A) (Draheim et al., 2016). Thus, both fixed and live fluorescence
microscopy results implicate Ser10 and Ser25 in regulating ICAP1 nuclear
localization.

Finally, using lentivirally transduced GFP, ICAP1-GFP, ICAP1-GFP S10A, and
ICAP1-GFP S10E, I show that the ICAP1 S10A mutation enhances while the
ICAP1 S10E mutation inhibits ICAP1 nuclear accumulation compared to wt ICAP1
in both CHO (Fig. 2.4A-B) and EA.hy926 endothelial-like cells (Fig. 2.4D-E). Viral
transduction allows visualization of multiple GFP-positive cells in each panel,
clearly demonstrating the impact of the S10 phosphomutation on ICAP1
localization (Fig. 2.4A,D). Constructs were expressed at the expected size by
immunoblotting (Fig. 2.4C,F). Therefore, both transiently transfected and
lentivirally transduced ICAP1 phosphomutants alter ICAP1 localization.
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Figure 2.4: Mutations at S10 alter localization of lentivirally transduced
ICAP1 in CHO and EA.hy926 cells.
CHO cells (A-C) or EA.hy926 cells (D-F) were transduced with lentivirus encoding
GFP, wt ICAP1-GFP, ICAP1-GFP S10A, or ICAP1-GFP S10E phosphomutants,
and selected with Hygromycin. Representative images of transduced CHO (A) or
EA.hy926 (D) cells stained with DAPI (to identify nuclei) and Phalloidin (to identify
cell boundaries) 24 hours after plating on fibronectin are shown. Bar represents 50
µm. The percentage of total GFP signal in the nucleus of transduced CHO (B) or
EA.hy926 (E) cells was plotted. Boxes represent 25-50 and 50-75 percentile,
whiskers show the 10-90 percentile, + indicates mean. Results are from 3
independent experiments and the total number of cells examined (N) is indicated
for each condition. **** indicates statistical significance at p≤0.0001 as determined
by a one-way ANOVA with Fisher’s LSD test with multiple comparisons. (C,F)
Representative anti-GFP immunoblots indicate expression of individual
phosphomutants at the expected size. Vinculin staining was used as a loading
control.
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2.3.3: ICAP1 Ser10 and Ser25 influence localization independently of the
ICAP1 PTB domain
The PTB domain accounts for 134 of the 200 amino acids in ICAP1 and contains
binding sites for β1 integrins and KRIT1 (Liu et al., 2013), but is dispensable for
nuclear localization (Draheim et al., 2016) (Fig. 2.5A). However, phosphorylation
could theoretically affect either intermolecular or intramolecular interactions with
the PTB domain to control nuclear import. To test whether the PTB domain is
required for the ability of phosphorylation site mutants to impact ICAP1 localization,
I introduced phospho-mimicking and phospho-blocking mutations into the isolated
N-terminal region (GFP-ICAP1 1-45). Analysis by quantitative microscopy
revealed that the N-terminal region localized similarly to full-length ICAP1 (Fig.
2.5B), suggesting that the ICAP1 PTB domain does not contain any regions (e.g.,
nuclear export sequence) that impact ICAP1 localization or mask the NLS.
Furthermore, mutations at Ser10 or Ser25 had comparable effects on full-length
and N-terminal ICAP1 localization (Fig. 2.5B). These results suggest that
phosphorylation at these residues does not alter nuclear localization by changing
PTB domain interactions or regulating NLS exposure by releasing the proposed Nterminal region:PTB domain interactions (Millon-Fremillon et al., 2013).
Immunoblots show all constructs expressed at the expected molecular weights
(Fig. 2.5C, Fig. S1D). Overall, the phosphorylation site mutant analysis revealed
that phospho-mimicking mutations at Ser10 and Ser25 lead to decreased ICAP1
nuclear accumulation while the corresponding phospho-blocking mutations
enhance ICAP1 nuclear localization, that Ser10 is the major site governing ICAP1
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localization, and that the effects of phosphomutants on ICAP1 localization do not
require the ICAP1 PTB domain.
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Figure 2.5: Residues 46-200 do not alter ICAP1 localization.
(A) Schematic depicting GFP-ICAP1 and the truncation mutant GFP ICAP1 1-45.
(B) Percentage of GFP intensity in the nucleus of CHO cells expressing GFP
(unfilled box) or phosphomutants of GFP-tagged full-length ICAP1 (blue boxes) or
ICAP1 1-45 (yellow boxes) 24 hours after plating on fibronectin. Results are from
3 independent experiments and the total number of cells examined (N) is indicated
for each condition. Boxes represent 25-50 and 50-75 percentile, whiskers show
the 10-90 percentile and a + indicates mean. Statistical analysis was performed
using a one-way ANOVA with Fisher’s LSD test with multiple comparisons. (C)
Representative immunoblots (against anti-GFP and anti-Vinculin) indicate
construct expression at the expected sizes. Note that GFP (lane 1) runs at a
smaller size than GFP-ICAP1 1-45 (lanes 7-11).
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2.3.4: PAK4 phosphorylates ICAP1 at Ser10
The aforementioned findings suggest that ICAP1 nuclear localization can be
inhibited by phosphorylation at Ser10, and to a lesser extent at Ser25. However,
the point mutants I generated could theoretically affect localization independently
of

phosphorylation,

for

example

by

disrupting

other

post-translational

modifications. In order to test whether authentic phosphorylation was important for
localization, I sought kinases that can phosphorylate ICAP1 at these positions.
Ser10 falls within a consensus phosphorylation site motif for type II PAKs (PAK4,
5, and 6) (Rennefahrt et al., 2007; Ha et al., 2015) (Fig. 2.6A). To determine
whether type II PAKs could indeed phosphorylate ICAP1, I performed in vitro
radiolabel PAK4 kinase assays using recombinant GST-ICAP1 as a substrate.
PAK4 catalytic domain robustly phosphorylated GST-ICAP1. While mutation of
Ser25 alone was without effect, phosphorylation of GST-ICAP1 S10A and
S10A/S25A was diminished approximately 10-fold (Fig. 2.6B,C). These
experiments indicate that PAK4 catalytic domain phosphorylates ICAP1 at S10 but
not S25 in vitro.
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Figure 2.6: PAK4 catalytic domain phosphorylates ICAP1 S10 but not S25 in
vitro.
(A) Alignment of the substrate recognition motif of the type II PAKs and the ICAP1
S10 site. (B,C) In vitro kinase assays were performed by incubating GST-ICAP1
or phosphomutants, PAK4 catalytic domain, and [γ-33P]ATP for 30 min. (B)
Representative autoradiograph and corresponding Coomassie stained gel. (C)
Phosphorylation of GST-ICAP1 mutants was quantified and normalized to wt GSTICAP1 in 4 independents experiments. Individual values are represented by filled
circles, bars show mean with standard deviation. **** indicates p≤0.0001 with
respect to wt GST-ICAP1 as determined by a one-way ANOVA test with Fisher’s
LSD test with multiple comparisons.
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To address whether PAK4 could phosphorylate ICAP1 at Ser10 in cells, I
performed phosphate affinity gel analysis, which relies on the reduced migration
of phosphorylated proteins when fractionated by SDS-PAGE in the presence of
polyacrylamide-bound Phos-tagTM reagent (Kinoshita et al., 2006). To maximize
the potential mobility shift, I initially used GFP-ICAP1 residues 1-45 since this
construct targets to the nucleus like full-length ICAP1 (Fig. 2.5B) (Rothbauer et
al., 2008; Kadry et al., 2018, 2). To investigate PAK4-mediated phosphorylation,
CHO cells were co-transfected with mCherry or hyperactivate mCherry-PAK4
S445N mutant (Qu et al., 2001) and GFP-tagged ICAP1 constructs. GFP-tagged
proteins were isolated from cell lysates, mock-treated or lambda protein
phosphatase-treated, and fractionated by Phos-tagTM or standard SDS-PAGE, and
immunoblotted with an anti-GFP antibody (Fig. 2.7A). In Phos-tagTM gels, line
scans depicting signal intensity exhibited as least three GFP-ICAP1 1-45 species,
which I interpret as an unphosphorylated and two slower migrating phosphorylated
forms (Fig. 2.7B). Lambda protein phosphatase treatment resulted in loss of most
of the upper two bands, supporting this interpretation (Fig. 2.7A,B). Notably, when
mCherry-PAK4 was co-expressed with GFP-ICAP1 1-45, the intensity of the
intermediately migrating band (phosphospecies 1) was substantially increased,
indicating enrichment of this phosphospecies (Fig. 2.7A,B). This enrichment
required Ser10, as phosphospecies 1 was largely absent in the GFP-ICAP1 1-45
S10A mutant (Fig. 2.7A,B). Multiple independent replicates confirmed the
dependence of phosphospecies 1 on the ICAP1 Ser10 site (Fig. 2.7C). These data
strongly suggest that when co-expressed, PAK4 phosphorylates Ser10 of ICAP1.
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To test whether PAK4 phosphorylates full-length ICAP1 in cells, I used ICAP1 with
a short C-terminal Spot-tag® (ChromoTek). Phos-tagTM gel analysis was
performed on ICAP1 isolated from CHO cells co-expressing mCherry or mCherryPAK4 S445N mutant (Qu et al., 2001) and C-terminal Spot-tagged® ICAP1
(ICAP1-Spot) or ICAP1-Spot S10A. Line scans revealed two ICAP1-Spot species,
likely a lower unphosphorylated species and a slower migrating phosphospecies
that was largely lost upon phosphatase treatment (Fig. 2.7D-F). When mCherryPAK4 S445N was co-expressed with ICAP1-Spot, the signal of the phosphorylated
band was significantly enriched while that of the unphosphorylated band
decreased (Fig. 2.7D-F). However, when ICAP1-Spot S10A was co-expressed
with mCherry-PAK4 S445N compared with mCherry, no changes between the ratio
of phosphorylated to unphosphorylated species was detected, indicating that the
enrichment of the phosphorylated species seen with PAK4 S445N and wt ICAP1
is specific to the Ser10 site (Fig. 2.7D-F). Therefore, Phos-tagTM analysis using
both GFP-ICAP1 1-45 and full-length ICAP1-Spot constructs specifically revealed
a phosphorylated species in the presence of activated PAK4 that was largely
absent with the corresponding S10A mutant.
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Figure 2.7: Activated PAK4 phosphorylates ICAP1 S10 in cells.
Phos-tagTM gel mobility shift analyses were performed in CHO cells co-expressing
mCherry, mCherry-PAK4 S445N and either GFP, GFP-ICAP1 1-45, or GFP-ICAP1
1-45 S10A (A-C) or ICAP1-Spot or ICAP1-Spot S10A (D-F) in the presence and
absence of lambda protein phosphatase (λPP). (A-C) GFP-nanotrap pulldowns
were resolved by Phos-tagTM PAGE and by standard SDS-PAGE (as indicated)
and analyzed by immunoblotting against GFP (A). Input samples were also
assessed by standard SDS-PAGE to evaluate expression levels of all constructs.
(B) Line scans (outlined by blue boxes) depicting signal intensities of mobility shift
bands of GFP-ICAP1 1-45 or GFP-ICAP1 S10A 1-45 from (A) in conditions with
mCherry, mCherry-PAK4 S445N alone, or mCherry-PAK4 S445N with λPP. (C)
Percentages of the signal in each of the mobility shift bands of GFP-ICAP1 1-45
or GFP-ICAP1 S10A 1-45 were calculated by dividing the signal intensity of each
band by the total amount of ICAP1. Data are represented as mean ± standard
deviation from independent preparations. (D-E) Spot-Trap® agarose pulldowns
(D), were resolved by Phos-tagTM PAGE and by standard SDS-PAGE and
analyzed by immunoblotting against ICAP1 (D). Input samples were also assessed
by standard SDS-PAGE to evaluate expression levels of all constructs. (E) Line
scans (outlined by blue boxes) depicting signal intensities of mobility shift bands
of ICAP1-Spot or ICAP1-Spot S10A from (D) in conditions with mCherry, mCherryPAK4 S445N alone, or mCherry-PAK4 S445N with λPP. (F) Percentages of the
signal in each of the mobility shift bands of ICAP1-Spot or ICAP1-Spot S10A were
calculated by dividing the signal intensity of each band by the total amount of
ICAP1. Data are represented as mean ± standard deviation from independent
preparations.
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2.3.5: PAK4 inhibits ICAP1 nuclear accumulation in a S10 dependent manner
Having shown that PAK4 phosphorylates ICAP1 on Ser10, I tested whether
activated PAK4 could alter ICAP1 localization in cells. CHO cells were cotransfected with GFP or GFP-PAK4 S445N and wt or mutant ICAP1-mCherry, and
nuclear localization was evaluated in double-positive cells. Notably, GFP-PAK4
S445N expression significantly reduced ICAP1-mCherry nuclear localization but
had no effect on mCherry localization (Fig. 2.8A,B). Importantly, GFP-PAK4
S445N did not alter the enhanced nuclear localization of ICAP1-mCherry
S10A/S25A or ICAP1-mCherry S10A (Fig. 2.8A,B). These data are consistent with
PAK4-mediated phosphorylation of ICAP1 at Ser10 inhibiting ICAP1 nuclear
accumulation and blockade of phosphorylation by S10A mutations. Interestingly,
GFP-PAK4 S445N did modestly, but significantly, inhibit nuclear localization of
ICAP1-mCherry S25A, consistent with the results for the ICAP1 S10E/S25A mixed
phosphorylation site mutant (compare Fig. 2.8B to Fig. 2.3C). This further
supports a model where Ser10 is the major phosphorylation site governing ICAP1
localization, but that modification of Ser25 can modulate this effect.

The preceding data suggest that GFP-PAK4 S445N reduces ICAP1-mCherry
nuclear accumulation by phosphorylating ICAP1 at Ser10. Immunostaining
indicates that PAK4 is predominantly cytoplasmic (Fig. 2.8A), suggesting that
phosphorylation occurs in the cytosol. To exclude potential kinase-independent
effects of PAK4, I used hyperactive, wt and kinase-dead PAK4 to investigate
whether ICAP1 localization depends on PAK4 kinase activity. In separate
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experiments, I confirmed the relative kinase activities of these constructs by cotransfecting with the type II PAK substrate, Pacsin-1, and blotting for phosphoPacsin-1, as previously described (Gao et al., 2013). I found that GFP-PAK4
S445N was more active than wt PAK4, but that kinase inactive GFP-PAK4 K350M
mutant (Abo et al., 1998, 4) failed to phosphorylate Pacsin-1 (data not shown).
Analysis of ICAP1 localization showed that kinase inactive PAK4 had no significant
effect on ICAP1-mCherry nuclear localization, while wt PAK4 produced a slight,
but significant, reduction in ICAP1-mCherry nuclear localization that was
enhanced with the activating S445N mutation (Fig. 2.8C). Co-expression with any
PAK4 construct did not impact localization of ICAP1-mCherry S10A/S25A or of
mCherry alone (Fig. 2.8C). Thus, use of PAK4 mutants with altered kinase activity
and

ICAP1

S10A

mutants

supports

a

model

where

PAK4-mediated

phosphorylation of Ser10 inhibits ICAP1 nuclear localization.

2.3.6: PAK6 also inhibits ICAP1 nuclear accumulation
The similarity in substrate specificity between type II PAKs suggests that other type
II PAKs might also modulate ICAP1 localization. Consistent with this, analysis of
PAK6 showed that hyperactive PAK6 P52L (Gao et al., 2013) but not kinase dead
PAK6 K436M (Schrantz et al., 2004) led to a statistically significant decrease in
ICAP1-mCherry localization but had no effect on ICAP1-mCherry S10A/S25A
localization (Fig. 2.8D). The effect of PAK6 P52L on ICAP1 localization was less
pronounced than that of PAK4 S445N, but this is likely due to differences in kinase
activity as PAK4 S445N led to a higher level of Pacsin-1 phosphorylation than
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PAK6 P52L did upon co-expression (data not shown). Taken together, my data
further support the hypothesis that phosphorylation of ICAP1 on Ser10 inhibits
ICAP1 nuclear localization.
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Figure 2.8: Activated PAK4 or 6 prevents ICAP1 nuclear accumulation.
(A-D) CHO cells expressing mCherry, ICAP1-mCherry, or ICAP1-mCherry
phospho-blockers and GFP or GFP-PAK4 (A-C) or PAK6 (D) constructs were
plated on fibronectin, fixed 24 hours later and stained with DAPI to identify nuclei.
(A) Representative images, bar represents 10 µm. (B-D) Percentage of mCherry
intensity in the nucleus of mCherry and GFP double positive cells. Results are from
4-6 independent experiments and the total number of cells examined (N) is
indicated for each condition. Boxes represent 25-50 and 50-75 percentile, whiskers
show the 10-90 percentile and a + indicates mean. Statistical analysis was
performed using a one-way ANOVA with Fisher’s LSD test with multiple
comparisons. **** indicates p≤0.0001, ** indicates p≤0.01.
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2.3.7: ICAP1 phospho-mimicking mutants and PAK4 S445N inhibit KRIT1
nuclear accumulation
The Calderwood lab has previously shown that ICAP1 directs KRIT1 to the nucleus
(Draheim et al., 2016). This process requires the ICAP1:KRIT1 interaction and
depends on the ICAP1 NLS (Draheim et al., 2016). Therefore, I asked whether
mutation of ICAP1 phosphorylation sites would also alter KRIT1 localization. CHO
cells

co-expressing

GFP,

GFP-KRIT1,

or

GFP-KRIT1

R179A/R185A/N192A/Y195A (KRIT1ICAP1; KRIT1 mutant defective in binding
ICAP1) (Draheim et al., 2016) and mCherry, ICAP1-mCherry, or ICAP1-mCherry
phosphomutants were examined by fluorescence microscopy, and nuclear GFP
and mCherry signals were calculated. As expected, in the presence of coexpressed GFP, GFP-KRIT1, or GFP-KRIT1ICAP1, ICAP1-mCherry was largely
nuclear, while S10A/S25A mutations further enhanced ICAP1 nuclear localization
and S10E/S25E mutations inhibited ICAP1 nuclear accumulation (Fig. 2.9A,B).
However, when GFP-KRIT1 localization was examined, ICAP1 substantially
increased KRIT1 nuclear localization (Fig. 2.9A,C). This was further increased by
ICAP1-mCherry S10A/S25A while ICAP1-mCherry S10E/S25E retained KRIT1 in
the cytoplasm (Fig. 2.9A,C). Thus, KRIT1 localization is driven by ICAP1. This
effect requires ICAP1:KRIT1 interaction as GFP-KRIT1ICAP1 (Draheim et al., 2016)
that fails to bind ICAP1 does not follow ICAP1 localization and instead remains
largely

cytoplasmic

(Fig.

2.9C).

Altogether,

these

data

suggest

that

phosphorylation of ICAP1 could alter KRIT1 localization in a manner dependent
on their direct association.
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To study whether phosphorylation inhibits nuclear accumulation of the
ICAP1/KRIT1 complex, I examined nuclear localization of CHO cells coexpressing C-terminally triple FLAG tagged ICAP1 (ICAP1-FLAG) or ICAP1-FLAG
S10A, and mCherry or mCherry-PAK4 S445N, and GFP or GFP-KRIT1. As
expected, cells expressing mCherry, ICAP1-FLAG, and GFP-KRIT1 shifted GFPKRIT1 more strongly nuclear (~63%, compared to ~45% nuclear GFP-KRIT1 with
mCherry and FLAG) (Fig. 2.9D). Importantly, with mCherry-PAK4 S445N and
ICAP1-FLAG, GFP-KRIT1 became more diffusely localized (~55% nuclear) (Fig.
2.9D). Further, this shift in KRIT1 localization is dependent on the ICAP1 Ser10
site, as the effect of PAK4 S445N was prevented when KRIT1 was co-expressed
with ICAP1 S10A (Fig. 2.9D). This experiment suggests that phosphorylation at
ICAP1 Ser10 can prevent KRIT1 nuclear accumulation.
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Figure 2.9: Serine phosphorylation of ICAP1 impairs KRIT1 nuclear
accumulation.
(A-D) CHO cells expressing mCherry, ICAP1-mCherry, or ICAP1-mCherry
phosphomutants and GFP, GFP-tagged KRIT1 or a KRIT1 mutant defective in
binding ICAP1 (KRIT1ICAP1; GFP-KRIT1 R179A/R185A/N192A/Y195A) were
plated on fibronectin, fixed 24 hours later and stained with DAPI to identify nuclei.
(A) Representative images, bar represents 10 µm. (B,C) The percentage of
mCherry (B) or GFP (C) signal in the nucleus of GFP and mCherry double positive
cells. Results are from 3 independent experiments and the total number of cells
examined (N) is indicated for each condition. Boxes represent 25-50 and 50-75
percentile, whiskers show the 10-90 percentile, and the mean is shown with a +.
Statistical analysis was performed using a one-way ANOVA with Fisher’s LSD test
with multiple comparisons. **** indicates p≤0.0001. (D) CHO cells co-expressing
FLAG, C-terminally triple FLAG tagged ICAP1 (ICAP1-FLAG) or ICAP1-FLAG
S10A, with mCherry or mCherry-PAK4 S445N, and GFP or GFP-KRIT1 constructs
were plated on fibronectin, fixed 24 hours later and stained with DAPI (to identify
nuclei). (D) Nuclear GFP was calculated in double GFP and mCherry positive cells
in 4 independent experiments and presented as in (C).
105

2.4 Discussion
ICAP1 plays critical roles in vascular biology (Brütsch et al., 2010; Faurobert et al.,
2013). Further, ICAP1 binds, stabilizes, and regulates the localization of KRIT1
(Chang et al., 1997; Zhang and Hemler, 1999; Faurobert et al., 2013; Draheim et
al., 2016), a protein essential for vascular development and whose loss results in
CCM (Kurth et al., 1994; Marchuk et al., 1995; Whitehead et al., 2004). The
Calderwood lab has shown that the NLS in ICAP1 drives both ICAP1 and KRIT1
nuclear localization (Draheim et al., 2016). Now, using ICAP1 phosphorylation site
mutants and PAK4, a kinase that I show can phosphorylate ICAP1, I find that
phosphorylation at Ser10 impairs ICAP1 nuclear accumulation and that this in turn
impacts nuclear localization of KRIT1.

2.4.1: Regulation of ICAP1 by phosphorylation
ICAP1 is composed of a PTB domain, which mediates interactions with both
integrin 1 and KRIT1, and a preceding unstructured region (residues 1-60) (Liu
et al., 2013; Draheim et al., 2016), which contains the NLS and is rich in serine
and threonine residues. Mass spectroscopic analysis of ICAP1 co-purified with
KRIT1 from U2OS cells revealed numerous phosphorylation sites in the N-terminal
region (Kim et al., 2011), but the role of this phosphorylation was unknown. As
phosphorylation at sites close to, or within, a NLS is a well-established mechanism
to inhibit nuclear accumulation (Harreman et al., 2004; Nardozzi et al., 2010), I
used ICAP1 phospho-mimicking mutations to assess the potential impact of ICAP1
phosphorylation on localization. Of the 15 potential serine phosphorylation sites

106

examined (Kim et al., 2011), only phospho-mimicking mutations at S10 and to a
lesser extent at S25, significantly inhibited nuclear localization. Furthermore, coexpressing ICAP1 with activated PAK4 (a kinase which I show to be capable of
phosphorylating ICAP1 Ser10) also inhibited nuclear accumulation of ICAP1. My
results were consistent across multiple cell types, unaffected by location or identity
of fluorescent protein tags, evident in fixed and live cells and could be obtained in
transiently transfected or stably transduced cells, strongly supporting a model
where phosphorylation generally inhibits ICAP1 nuclear import. However, one
caveat of my study is that it relies on exogenously expressed, tagged ICAP1. I
have been unable to identify an anti-ICAP1 antibody that is effective in
immunofluorescence staining or one that recognizes a single band in immunoblots,
complicating attempts to detect endogenous ICAP1. My efforts to study localization
of endogenous ICAP1 by subcellular fractionation (not shown) were limited by the
low expression level of endogenous ICAP1 and the lack of good anti-ICAP1
antibodies. I note the importance of investigating endogenous proteins in future
studies with improved reagents and approaches.

2.4.2: Kinases regulating ICAP1 nuclear localization
The mutagenic data described above suggest that phosphorylation at Ser10 or
Ser25 inhibits ICAP1 nuclear accumulation. Phosphorylation at these sites had
been resolved in cells by mass spectrometry (Kim et al., 2011), but the kinases
responsible had not been identified. While the kinase(s) mediating Ser25
phosphorylation remain unknown, my data establish that PAK4, a type II PAK, can
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phosphorylate ICAP1 at Ser10 in vitro and when co-overexpressed in cells.
Furthermore, active PAK4 and the closely related PAK6, but not their kinasedefective mutants, inhibit ICAP1 nuclear accumulation in a manner dependent on
Ser10. I initially tested PAK4 because the residues flanking Ser10 in ICAP1
conform to a preferred type II PAK substrate motif (Rennefahrt et al., 2007; Ha et
al., 2015). Indeed, despite the presence of 14 other Ser and Thr residues in the
ICAP1 N-terminal region, I found that PAK4 almost exclusively phosphorylates
Ser10. These data establish that PAK4 activity can inhibit nuclear localization of
ICAP1 via modification of S10, but do not allow me to conclude whether PAK4 (or
other type II PAKs) is the physiological ICAP1 kinase. Indeed, this may be cell type
dependent. However, like ICAP1 and KRIT1, PAK4 is important for proper vascular
development. PAK4 null mice die at embryonic day 11.5 (E11.5), and embryos
examined at E10.5 display vascular abnormalities in the developing heart including
thinning of the myocardium and dilation of the atrium and sinus venosus (Qu et al.,
2003). Deletion of PAK4 in the precursors of the secondary heart field also
produced heart defects in adult mice (Nekrasova and Minden, 2012). Furthermore,
PAK4 is a downstream effector of Cdc42, a protein whose deletion can result in
CCM lesions in mice (Castro et al., 2019). Additionally, together with CCM2, PAK4
enhances endothelial barrier function through mediating atrial natriuretic peptide
signaling (Miura et al., 2017), further suggesting that PAK4 may play a role in CCM
signaling pathways.
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PAK4 substrates important for its effects on the vasculature are not clearly defined,
raising the possibility that PAK-mediated inhibition of nuclear accumulation of
ICAP1 and KRIT1 might have an important role. As both Ser10 and Ser25 lie in
serine-rich regions, ICAP1 phosphorylation at nearby sites by other kinases may
alter Ser10 or Ser25 phosphorylation and hence indirectly modulate nuclear
translocation. In particular, the ROCK kinases, whose expression is hyperactivated
in CCM lesions, may be interesting physiologically-relevant kinases to explore.

2.4.3: Mechanisms by which phosphorylation may regulate ICAP1
localization
I found that the effect of phosphorylation on nuclear localization of ICAP1 was
independent of its PTB domain. This effectively eliminates the possibility that
Ser10 or Ser25 phosphorylation acts by triggering N-terminal region:PTB domain
interactions that mask the NLS. While NLS masking by phosphorylation-induced
conformational changes within the N-terminal sequence are theoretically possible,
this region is predicted to be largely unstructured, suggesting more direct effects
of phosphorylation on nuclear import. ICAP1 contains a classic basic NLS at
residues 6-9 (KKHR) that is likely to be recognized by the acidic, hydrophobic NLSbinding groove of importin-α (IMP-α), a nuclear import receptor that binds classic
NLSs to facilitate nuclear transport (Harreman et al., 2004; Wagstaff and Jans,
2006; Nardozzi et al., 2010). Given that Ser10 is the residue immediately following
the NLS, its phosphorylation may disrupt the interaction between the NLS and IMPα, preventing ICAP1 nuclear import. However, I note that despite falling within a

109

stretch of five serine residues, only modification of Ser10 alters nuclear
accumulation, showing that the effect is specific to this residue. Furthermore,
mutations at Ser25, which is even more distant from the NLS, also affect nuclear
localization. Rather than inhibiting binding to the nuclear import machinery,
phosphorylation may alternatively inhibit nuclear import by facilitating binding to
cytoplasmic anchors. Further studies will be required to distinguish between these
possibilities.

2.4.4: Potential nuclear roles of ICAP1
Although ICAP1 has now been observed in the nucleus by several groups
(Fournier et al., 2005b; Zawistowski, 2005; Francalanci et al., 2009; Liu et al.,
2013; Draheim et al., 2016), its role there is not well established. It has been
reported that ICAP1 increases cellular proliferation by activating c-Myc
transcription and that this effect requires the NLS (Fournier et al., 2005b), but it is
unclear if this is a direct consequence of ICAP1 nuclear compartmentalization.
ICAP1 nuclear translocation also recruits KRIT1 to the nucleus (Draheim et al.,
2016) and I have shown here that phosphorylation of ICAP1 prevents KRIT1
accumulation in the nucleus. KRIT1 has been observed at perichromatin fibrils and
the nucleolar dense fibrillar component, sites of active transcription (Marzo et al.,
2014), but its function at these locations is unknown. However, loss of KRIT1
expression results in altered gene expression (Goitre et al., 2010, 2017; DiStefano
et al., 2014; Zhou et al., 2015b, 2016b; Cuttano et al., 2016; Lopez-Ramirez et al.,
2017, 2019), notably including a decrease in expression of angiogenesis-related
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(DiStefano et al., 2014; Zhou et al., 2015b, 2016b; Cuttano et al., 2016; LopezRamirez et al., 2017, 2019) and anti-oxidant (Goitre et al., 2010, 2017) genes.
Whether nuclear KRIT1 is involved in modulating the expression of these genes is
yet to be determined as CCM proteins can also influence cytoplasmic signaling
cascades that activate ERK5, hence altering gene transcription (Fisher et al.,
2015a; Zhou et al., 2015b). Further investigation of the nuclear functions of ICAP1
and KRIT1 is a priority, and the ability to direct ICAP1 and the ICAP1/KRIT1
complex to distinct cellular compartments by phosphorylation should aid these
studies.

2.4.5: Implications for understanding ICAP1 and KRIT1-dependent vascular
defects and CCM disease
Both ICAP1 and KRIT1 play roles in the vasculature. ICAP1 null mice display
vascular abnormalities such as increased vessel permeability and dilation
(Faurobert et al., 2013), while KRIT1 knockout mice are embryonic lethal with
primarily vascular defects (Whitehead et al., 2004). Further, loss of KRIT1 results
in CCM, and ICAP1 function is likely impaired in CCM given ICAP1’s tight
association with KRIT1 (Zawistowski et al., 2002; Faurobert et al., 2013; Draheim
et al., 2016). While much of the focus on KRIT1 in regulating endothelial cell
function has been on its cytoplasmic or cell-cell junctional roles (Glading et al.,
2007; Glading and Ginsberg, 2010; Lopez-Ramirez et al., 2017), my observation
of kinase-regulated ICAP1-mediated translocation of KRIT1 to the nucleus
suggests that nuclear functions of KRIT1 should also be considered.
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Appendix: The KRIT1:CCM2 stoichiometry in MEKK3-MEK5-ERK5 signaling
and other phenotypes
A.1 Introduction
KRIT1 and CCM2 are well-established binding partners, and this interaction has
been shown by co-IP (Zawistowski, 2005) and by yeast two-hybrid screening
(Zhang et al., 2007). More recently, the Boggon group mapped the KRIT1:CCM2
interaction by crystal structure, and found that double mutations at the second and
third KRIT1 NPxY motifs caused a reduction in co-IP (Fisher et al., 2015b). They
further showed that the CCM2 PTB domain preferentially binds the third KRIT1
NPxY/F motif in vitro and validated this by introducing point mutations in these
domains to impair binding by pulldown assay (Fisher et al., 2015b). However, since
then, the Boggon group also has unpublished crystallographic data suggesting that
CCM2 binds KRIT1 in a 2:1 ratio. How this binding interaction impacts downstream
CCM2 and KRIT1 signaling and functions is unknown. I sought to investigate this
interaction functionally through knockdown rescue experiments using wildtype (wt)
KRIT1 or CCM2-binding defective KRIT1 mutants in EA.hy926 endothelial-like
cells and assessed relevant phenotypes, including the MEKK3-MEK5-ERK5KLF2/4 signaling cascade, KRIT1 and CCM2 protein expression, endothelial
network formation, and cell growth.
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A.2 Materials and Methods
A.2.1: Antibodies/cDNA
Anti-GFP (Rockland, catalogue #600-101-215), anti-KRIT1 (Abcam, ab146025),
anti-vinculin (VCL, Sigma, V-9131), anti-beta-tubulin (DSHB, E7-5), anti-myc-tag
(CST, 9B11), and anti-CCM2 (Abcam, ab53557) antibodies were purchased. Wildtype and mutant CCM2 (Draheim et al., 2015) and KRIT1 (Liu et al., 2013; Draheim
et al., 2016) cDNAs previously used for protein expression/purification were
subcloned. Additional mutations were introduced by QuikChange site-directed
mutagenesis (Stratagene). Lentiviral KRIT1 and CCM2 expression constructs
were generated by subcloning into CMV-pLENTI-Hygro (Addgene). All constructs
used were authenticated by DNA sequencing.
A.2.2: Cell Culture
EA.hy926 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
containing 9% fetal bovine serum (FBS), 1X sodium pyruvate, 1X nonessential
amino acids, and 1X HAT supplement (Gibco). Mouse Lung Endothelial Cells
(MLECs), a gift from Dr. William Sessa’s lab, were cultured in Endothelial Cell
Growth Basal medium with supplements and growth factors (Lonza) and 5% FBS.
HeLa and HEK293T cells were cultured in DMEM with 9% FBS.
A.2.3: Endothelial Network Formation
Network formation in the EA.hy926 cell line was assayed as described previously
(Jones et al., 1998; Draheim et al., 2015). Cells were grown in 60-mm tissue culture
dishes until confluent, and growth media was replaced with serum-free DMEM with
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HAT supplement for 36 h after which the media was replaced with DMEM with HAT
supplement and 2.5% ethanol for 3 h. Glass-bottom dishes (Mattek) were evenly
coated with growth factor–reduced Matrigel (75 µL/well) and the Matrigel was
allowed to solidify at 37°C for 30 min. Ethanol-stimulated cells were trypsinized,
counted, and resuspended at 4 × 105 cells/ml in phenol red-free DMEM containing
HAT and 0.5% FBS. 2 ml of cell suspension was plated onto the Matrigel-coated
well and imaged live at 37°C and 5% CO2 for about 20 h using the phase channel
with a Nikon Ti-2 Eclipse microscope (Nikon, Tokyo, Japan) with a Prime95B
RoHS cMOS camera (pixel size 110 nm) (Photometrics, Tucson, AZ) with 10x
objective. Network formation was quantified by counting the number of connected
cells in randomly selected fields and dividing by the total number of cells in the
same field. To distinguish networks from cell clumps, a network was defined as
containing a minimum of five cells connected in a linear or branched fashion such
that a single segment has more cells along the length than the width. Networks
were also assessed by counting the number of nodes (defined as the junction point
of at least three segments), and normalized per 100 cells in the field.
A.2.4: Growth Assay
EA.hy926 cells were plated in wells of 6-well plates at 40,000 or 50,000 cells per
well in a 1 mL cell suspension with DMEM supplemented with 9% FBS and 1%
sodium pyruvate and 1% non-essential amino acids and incubated at 37°C with
5% CO2. After 3 days, cells were trypsinized, counted using a hemocytometer, and
replated at 40,000 or 50,000 cells per well, and the process was repeated every
three days. Cells were plated at ~20% density to allow for optimal cell growth.
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Measurement of cell proliferation was performed by taking fold change and log
transform values using Excel.
A.2.5: qPCR
Total RNA was extracted using a RNeasy kit (Qiagen) with DNase digestion. One
microgram of total RNA was used for cDNA synthesis with the iScript cDNA
synthesis kit (Bio-Rad) as per the manufacturer’s suggestion. Real-time PCR was
performed on a Bio-Rad CFX Connect Real-Time System and relative mRNA level
was calculated in CFX Manager software using the 2(−ΔΔCt) method. Error bars
represent the standard error of the mean from triplicate conditions from one
experiment. GAPDH and/or ActinB mRNA were used as internal controls. Human
PCR primer sequences are listed below:
Gene/region
GAPDH
ACTB
KRIT1
KLF2
KLF4

Forward Primer
GAAGGTGAAGGTCGGAGTC
A
GGACCTGACTGACTACCTC
AT
GTCTGTAGTGAATCCAGTAC
TC
CTACACCAAGAGTTCGCATC
TG
AGAGTTCCCATCTCAAGGG
CA

Reverse Primer
TTGAGGTCAATGAAGGGGT
C
CGTAGCACAGCTTCTCCTT
AAT
ACGTTCATCTAACCACTTAT
CC
CCGTGTGCTTTCGGTAGTG
GTCAGTTCATCTGAGCGGG

A.2.6: Protein Stability
Knockdown rescue experiments were performed to assess the role of the
KRIT1:CCM2 stoichiometry on protein stability. KRIT1 and CCM2 knockdown
rescue EA.hy926 cell lines were generated by knocking down KRIT1 or CCM2 and
115

rescuing with wildtype or binding defective KRIT1 or CCM2, and protein levels
assessed by immunoblotting. Cells were lysed directly in 1x sample buffer, needle
sheared 5x, and boiled at 95°C for 5-10 minutes before loaded onto a 12% SDSpolyacrylamide gel. Samples were transferred to 0.45 µm nitrocellulose
membranes, and membranes were blocked for 1 h in 5% BSA in TBS-T.
Immunoblotting was performed with primary antibodies diluted in 5% BSA in TBST, fluorescent secondary antibodies, and scanned on the Odyssey CLx IR imaging
system. Quantification was performed by obtaining signal intensities of bands with
background subtraction using Image Studio Lite.
A.2.7: Lentiviral Knockdown and Expression
Lentiviruses were produced by co-transfecting packaging vectors psPAX2 (viral
proteins Gag and Rev under the SV40 promoter; Addgene plasmid 12260, a gift
from D. Trono, École Polytechnique Fédérale de Lausanne, Lausanne,
Switzerland) and pMD2.G (viral protein VSV-G expressed under the CMV
promoter; Addgene plasmid 12259, a gift from D. Trono) into EA.hy926 cells with
the pLENTI-Hygro or pLKO construct. Viral supernatant was collected 48 and 72
h after transfection and filtered with a 0.45-m filter. To generate polyclonal
knockdown or expression lines, cells were incubated with viral supernatant and 8
g/ml Polybrene for 24 h. Cells were either analyzed 48–72 h post-infection or
selected with 50 g/ml hygromycin (CMV-pLENTI-Hygro) and/or 1 µg/mL puromycin
(pLKO) as appropriate.
A.2.8: Generation of CRISPR Cell Lines
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sgRNA oligos targeting the KRIT1 gene locus were generated using GPP sgRNA
Designer by the Broad Institute, and cloned into the pSpCas9(BB)-2A-GFP
(PX458) (Addgene) sgRNA scaffold. HeLa or HEK293T cells were transfected
using Lipofectamine 2000 or PEI following manufacturer’s instructions (Thermo
Scientific), and GFP positive cells were FACs sorted into 96 well plates using BD
FACSMelody 48 h after transfection. Following expansion of clones, knockout was
verified by immunoblotting against KRIT1 and sequencing. sgRNA oligos are listed
below:
Gene/region Oligo 1
CCAGTTAGATAGTGA
KRIT1
CCACT

Oligo 2
TCAACCAGTTAGATAGTGACCACT
GGGCAC

A.3 Preliminary Results and Discussion
The KRIT1:CCM2 stoichiometry and interaction in endothelial network
formation
One method to assess a protein’s role in vascular processes such as angiogenesis
is to measure the formation of endothelial networks using EA.hy926 endotheliallike cells plated on Matrigel to simulate in vitro angiogenesis (Jones et al., 1998).
Loss of any of the CCM proteins disrupts endothelial tube formation on Matrigel
(Borikova et al., 2010; Chernaya et al., 2018), and our lab has shown that the
defective networks seen in CCM2 and CCM3 knockdown lines are dependent on
the CCM2:CCM3 binding interaction (Draheim et al., 2015). I thus investigated
whether the KRIT1:CCM2 protein interaction and stoichiometry is necessary for
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their ability to form networks. First, shRNA-mediated KRIT1 knockdown in
EA.hy926 cells prevented network formation compared to cells expressing a
control scrambled shRNA (scr) (Fig. A.1A). Immunoblotting showed that KRIT1
levels were reduced by 73% (Fig. A.1B). Quantification of networks across 5
different fields of view revealed that while scr control cells formed about 4.8 nodes
per 100 cells, KRIT1 knockdown cells displayed no nodes (Fig. A.1C).
Furthermore, strikingly, while 100% of scr cells formed networks, 0% of shKRIT1
knockdown cells did so (Fig. A.1C). Similarly, CCM2 knockdown cell lines failed
to form networks compared to a scr control (Fig. A.1D). I note that the density of
cells plated affects their ability to form networks, hence scr cells may appear
phenotypically different based on plating density.
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Figure A.1: KRIT1 and CCM2 knockdown impairs network formation.
(A,D) EA.hy926 scr and KRIT1 or CCM2 knockdown lines were serum starved for
36 h, then ethanol stimulated for 3 h. Cells were trypsinized, washed, and replated
at ~400,000 cells in a Mattek glass bottom dish coated with Matrigel. Cells were
live-imaged for ~20 h at 10X using phase contrast at five different fields of view.
Images shown are a representative field of view 10-14 h after the start of plating
and imaging. (B) EA.hy926 cell lines shown in Fig. 1A immunoblotted for KRIT1
show ~73% knockdown of KRIT1 in the shKRIT1_79 cell line compared to scr
control. (C) Quantification of five different fields of view at about 10 h after the start
of plating and imaging, displaying the number of nodes per 100 cells and percent
of cells in networks. Data was collected and analyzed with the help of a rotation
student, Emma Carley.
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Having validated that knockdown of KRIT1 or CCM2 impairs network formation, I
tested whether reexpression of KRIT1 could rescue networks. Initially, I
overexpressed N-terminal GFP-tagged KRIT1 but found that this construct was
unable to rescue networks. Immunoblotting using an anti-KRIT1 antibody revealed
that this GFP-KRIT1 construct was highly overexpressed compared to
endogenous KRIT1 levels, suggesting that this may account for its inability to
rescue networks (Fig. A.2A). To address this issue, I generated C-terminally GFPtagged and untagged KRIT1 expression constructs and found their expression to
be reduced compared to the N-terminal GFP-tagged KRIT1, with untagged KRIT1
levels being comparable to that of endogenous KRIT1 (Fig. A.2A). I then
generated C-terminal myc-tagged wt and CCM2-binding deficient KRIT1
constructs as well as wt and KRIT1-binding deficient CCM2 constructs, harvested
virus, and transduced EA.hy926 cells. Knockdown rescue experiments are
currently being troubleshooted. Nevertheless, I have made the following
observations so far. First, the density of cells plated significantly affects their ability
to form networks: cells plated too sparsely result in lack of cell-cell contacts
necessary for network formation, while cells plated too densely result in quick
formation followed by collapse of networks. Second, KRIT1 expression greatly
determines the cells’ ability to form networks. While hyperexpression of GFPKRIT1 may prevent network formation, cells in which KRIT1 is not knocked down
to extreme levels can still form networks. Third, the quality and plating of Matrigel
affects the cells’ ability to form networks, and care must be taken to properly freeze,
thaw, and warm the Matrigel at precise time intervals in the plating process. Fourth,
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the amount of time the cells have been cultured affects their ability to form
networks. Further studies are needed to determine the optimal density of cell
plating and protein expression for these knockdown rescue studies, among other
factors.
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Figure A.2: GFP-KRIT1 is wildly expressed compared to untagged KRIT1
construct.
(A) Parental or KRIT1 knockout HEK293T cells were transfected with various
KRIT1 expression vectors, and KRIT1 protein levels were assessed by
immunoblotting using an anti-KRIT1 antibody. An anti-beta-tubulin antibody was
used as a loading control.
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Reexpression of CCM2 appears to rescue KRIT1 levels dependent on their
binding interaction
Previous studies have shown that the KRIT1:CCM2 interaction is necessary for
their stability. Specifically, loss of KRIT1 results in decreased CCM2 protein levels
while loss of CCM2 results in decreased KRIT1 levels, and this is dependent on
their binding interaction (Zawistowski, 2005; Zhang et al., 2007; Faurobert and
Albiges-Rizo, 2010; Fisher et al., 2015b). However, the studies to date have
focused on loss of function studies and none have shown whether rescue of KRIT1
or CCM2 is able to rescue its partner. Here, I attempt to elucidate the binding
interaction and stoichiometry of KRIT1 and CCM2 by rescuing with KRIT1 wt or
KRIT1 CCM2-binding defective mutants. I have generated KRIT1 and CCM2
knockdown rescue EA.hy926 cell lines and have shown that knockdown of CCM2
reduces levels of KRIT1 and that reexpression of wt CCM2 rescues KRIT1 levels,
while a CCM2 mutant defective in binding KRIT1 (CCM2_F217A) only partially
rescues KRIT1 levels (Fig. A.3A, B). Additional replicate experiments are
necessary to determine whether this result is statistically significant or
reproducible. The converse experiment to assess CCM2 levels upon KRIT1
knockdown and rescue is hampered by the lack of an anti-CCM2 antibody that
detects endogenous CCM2. Because of this, I will be unable to assess whether
the second or third NPxY motif of KRIT1 is necessary for the interaction and
stability of the CCM2:KRIT1 complex.
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Figure A.3: Reexpression of CCM2 appears to rescue KRIT1 levels
dependent on their binding interaction.
(A) EA.hy926 CCM wt or KRIT1-binding defective (F217A) knockdown rescue cell
lines were generated and processed for immunoblotting. Membranes were stained
using anti-CCM2 and anti-KRIT1 antibodies. Vinculin was used as a loading
control. Arrows denote protein of interest at expected molecular weight. (B)
Quantification was performed by obtaining signal intensities of bands with
background subtraction using Image Studio Lite.
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Knockdown of KRIT1 and CCM2 impairs cell growth and may be partially
rescued
Literature regarding the role of the CCM proteins on cell growth is inconsistent. For
instance, CCM3 has been reported to induce both cell proliferation and apoptosis
(Chen et al., 2009; Lauenborg et al., 2010; Louvi et al., 2011; Schleider et al.,
2011b; Lambertz et al., 2015), KRIT1 inhibits endothelial cell proliferation
(Wüstehube et al., 2010) but is also involved in pro-survival pathways (Guazzi et
al., 2012; Antognelli et al., 2017), and CCM2 triggers cell death (Harel et al., 2009)
but also signals to pro-survival proteins (Cullere et al., 2015). In EA.hy926, I
observed that knockdown of KRIT1 or CCM2 results in dramatic impairment in cell
proliferation compared to their scr counterparts, both when observed by eye and
when quantified in a growth assay (Fig. A.4A-D). These effects may be partially
rescued in a manner dependent on KRIT1 or CCM2 expression levels (Fig. A.4BD). I note that shCCM2+GFP cells display a drastic growth defect that precludes
the ability to passage them in culture. Only when the CCM2 knockdown cells were
rescued with wt or mutant CCM2 were they able to proliferate enough to passage
(Fig. A.4D). However, there are caveats with this study. First, all experiments were
only performed once and must be repeated before reaching conclusions. Second,
I have not been able to observe any differences in rescue of growth impairment
between wt CCM2 or KRIT1 and binding defective mutants, suggesting the binding
interaction may not be crucial to rescue growth (Fig. A.4C,D). First overexpressing
then knocking down the constructs also does not show differences. Third,
importantly, I have not been able to attain complete rescue with wt constructs,
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indicating that further optimization of the assay is needed. Lastly, the cells’ ability
to retain their knockdown or rescue phenotype drifts overtime, presumably
impacting their proliferative ability. Specifically, in the KRIT1 knockdown rescue
lines (Fig. A.4C), initial time points displayed stronger knockdown and
reexpression of KRIT1 protein levels by immunoblotting (day 6: ~69% knockdown
of KRIT1, 300% rescue) compared to at later time points (day 21: ~55%
knockdown, -9% rescue) (Fig. A.5A), suggesting a shorter length growth assay
may be more suitable for future studies.
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Figure A.4: Knockdown of KRIT1 and CCM2 impairs cell growth and may be
partially rescued.
(A-D). KRIT1 (A-C) and CCM2 (D) wt and mutant knockdown rescue EA.hy926
cell lines were generated and plated at 40,000 or 50,000 cells in wells of 6 well
plate. Every 3 days, cells were trypsinized, washed, counted, and replated at
40,000 or 50,000 cells per well. Fold change and log2fold change quantifications
were calculated and generated using Microsoft Excel.
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Figure A.5: KRIT1 knockdown and rescue lines drift overtime.
(A) KRIT1 wt and mutant knockdown EA.hy926 lines used in growth assay (Fig.
4C) were immunoblotted using antibodies against KRIT1 and Vinculin (loading
control) at Day 6 and 21 to assess KRIT1 protein levels. Arrows indicate protein of
interest at expected molecular weight. (B) Quantification was performed by
obtaining signal intensities of bands with background subtraction using Image
Studio Lite.
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KRIT1 knockdown results in elevated KFL2 and KLF4 mRNA levels and may
be partially rescued
Loss of KRIT1 and CCM2 result in hyperactivated MEKK3-MEK5-ERK5 signaling,
leading to upregulation of KLF2 and KLF4 (Zhou et al., 2015a, 2016b; Cuttano et
al., 2016), transcription factors that regulate endothelial biology (Atkins G. Brandon
and Jain Mukesh K., 2007; Sangwung et al., 2017). Here, I test whether loss of
KRIT1 in EA.hy926 recapitulates upregulated KLF2 and KLF4 mRNA levels by
qPCR, and whether rescuing with wt vs. CCM2 binding defective KRIT1 mutant
can rescue this phenotype. If the KRIT1:CCM2 binding stoichiometry and
interaction is necessary in preventing hyperactivated KLF2/4 levels, I expect that
wt KRIT1, but not a KRIT1 mutant with its second and third NPxY mutated to
reduce the elevated KLF2/4 levels. If I see results consistent with this hypothesis,
I will then test the importance of the 1:2 KRIT1:CCM2 binding stoichiometry by
examining if there are differences in rescue capability between the KRIT1 second
vs. third NPxY mutants. I have preliminarily shown that knockdown of KRIT1 in
EA.hy926 using the shRNA hairpin KRIT1_79 elevates KLF2 and KLF4 mRNA
levels dramatically in 3 independent experiments (Fig. A.6A). Cells knocked down
using a different shRNA targeting KRIT1 (82) also results in elevated KLF2 and
KLF4 levels compared to a scr control cell line (Fig. A.6B). Further, knockdown of
KRIT1 in MLECs (Fig. A.6C) and knockout of KRIT1 in HeLa cells upregulate KLF2
and KLF4 mRNA levels (Fig. A.6D). Rescue using untagged KRIT1 or C-terminal
myc-tagged KRIT1 results in partial reduction of the elevated KLF2 and KLF4
levels in EA.hy926 (Fig. A.7A,B). However, some difficulties with the assay include
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variability across different qPCR replicates, impaired growth of KRIT1 knockdown
cells, time dependency of KLF2/KLF4 upregulation upon KRIT1 knockdown, minor
changes in KLF2/4 levels upon KRIT1 knockdown and rescue, and drift in
knockdown and overexpression KRIT1 levels overtime. Further studies will be
necessary to optimize conditions for a strong induction in KLF2/KLF4 levels upon
KRIT1 knockdown that can be reproducibly rescued upon KRIT1 reexpression.
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Figure A.6: KRIT1 knockdown results in elevated KFL2 and KLF4 mRNA
levels.
EA.hy926 KRIT1_79 (A) and KRIT1_82 (B) knockdown cell lines, MLEC KRIT1_79
knockdown (C) cell lines, or HeLa KRIT1 knockout (D) cell lines were generated,
and mRNA levels of KLF2 and KLF4 were assessed by qPCR. KLF2 and KLF4
relative expression was normalized to GAPDH. Error bars represent the standard
error of the mean from triplicate conditions from one experiment.
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Figure A.7: KRIT1 knockdown results in elevated KFL2 and KLF4 mRNA
levels and may be partially rescued.
EA.hy926 KRIT1 knockdown (79) and rescue with untagged KRIT1 (A) or Cterminal myc-tagged KRIT1 (B) were generated, and mRNA levels of KLF2 and
KLF4 were assessed by qPCR. KLF2 and KLF4 relative expression was
normalized to GAPDH. KRIT1 mRNA levels show expected KRIT1 expression of
the various knockdown rescue cell lines.
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A.4 Conclusion and Future Directions
I have preliminarily shown that knockdown of KRIT1 or CCM2 results in defective
endothelial network formation, elevated KLF2/KLF4 mRNA levels, impaired cell
growth, and decreased protein expression of its binding partner. However, for each
of these processes, more experiments are needed before definitive conclusions
can be made. Once reproducible knockdown phenotypes are established, rescue
experiments with wt vs. mutant KRIT1 or wt vs. mutant CCM2 will need to be
optimized and replicated. Ultimately, if we are able to identify a knockdown rescue
phenotype that differs between wt and binding defective KRIT1 mutants, this will
help inform the KRIT1:CCM2 binding stoichiometry and interaction.
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